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1. Abstract  
 
This work presents results that constitute the required basis for establishing a successful 
structure-based Virtual Screening (VS) towards the identification of 20S proteasome inhibitors. 
The construction of this basis is divided into two aspects: i) structural and functional 
understanding of 20S proteasome and ii) a reliable method for analyzing VS results.  
This document consists of an introductory part where first is presented a brief review of the most 
important aspects of VS methodologies followed by a description of the biological relevance of 
20S proteasome as well as the current state proteasome inhibitors design. Subsequently, the 
preliminary VS results obtained which led to deeper understanding of the problem that forms the 
cardinal part of this dissertation are outlined. Thereafter the methodology is described depicting 
the analytical tools used in the development of the research. Finally, included in this work are 
two peer-reviewed publications that demonstrate the contribution to the development of 
protocols for the successful design of 20S proteasome inhibitors.  
In the first publication a Principal Component Analysis (PCA) on X-ray crystal structures of 20S 
proteasome’s β5 subunit unveils a domain movement induced upon peptidic inhibitor binding, 
thereby making possible to classify structures into pep- and apo-clusters. Similar displacements 
are observed in the mouse constitutive β5 subunit, but not in the mouse immuno β5 subunit, 
where the apo and liganded states are similar to the yeast structures in the pep-cluster. Further 
structural analysis, constituted by Molecular Dynamic simulations and a new X-ray crystal 
structure, confirmed the relevance that the peptide binding has on the induction of the observed 
domain motion. By assessing the implication that this structural transition has on the rest of the 
20S proteasome two possible allosteric pathways, which had been predicted previously in the 
literature, were found. These findings not only identify a completely new landscape of possible 
drugable pockets for an allosteric inhibition, but also provided a possible explanation for the 
enhanced peptidolytic activity observed in the immunoproteasome with respect to its constitutive 
counterpart. 
In the second publication an automated method for analyzing structure-based VS results was 
developed. The need for the development of this algorithm is based on the two aspects: i) 
current docking methodologies are able to identify the right binding mode for a single ligand 
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based on the docking score, but the same docking score is a rather inaccurate measure when 
comparing binding modes of different ligands, and ii) an important part of the VS protocol is still 
the human expertise in the evaluation of the docking binding modes aiming to identify false 
positives. To address these aspects, an Artificial Neural Network (ANN) is trained, validated and 
tested on VS benchmark. Each ligand has assigned features derived from the analysis of the 
docking data, which are the input on which the ANN evaluates the ligand changes of being an 
active inhibitor. The features are important aspects based on which an expert user would take 
the decision whether to trust or not the suggested docked molecule. The developed algorithm 
not only provides results comparable with the best of the methodologies found in the literature, 















2.1 Virtual Screening 
In the early stages of drug discovery process, a huge experimental effort is required to identify 
molecules capable to inhibit the activity of the target protein (Khanna 2012). Complications arise 
mainly from the vast amount of molecules that can compose the screening library (here also 
referred as chemical library). To reduce the experimental cost and to accelerate the process of 
identifying molecules with inhibitory capabilities (active molecules), a set of computational 
techniques, known as Virtual Screening (VS), have been devised (Tanrikulu, Krüger et al. 
2013). 
VS techniques can be divided in ligand-based and structure-based (Scior, Bender et al. 2012). 
In the ligand-based approach, the search on the chemical library is performed to identify 
molecules that share similar characteristics to that of previously known active molecules, that is, 
actual binders or ligands. In the structure-based approach atomic models of both, the protein´s 
active site and screening molecule, are used to evaluate their binding affinity. In this case, 
estimating the binding affinity of each molecule in the chemical library conforms the screening. 
This structure-based approach is preferred when novel lead compounds are a prerequisite 
(Drwal and Griffith 2013). In following section is provided a brief description on the main aspects 
of the structured-based approach (from now on referred to as docking).  
 
2.1.1 Docking  
The objective of the docking procedure is to accurately predict the binding affinity of a molecule 
(from now on also referred as ligand) in the protein's active site by evaluating the atomic 
interactions that conforms the binding complex(Xuan-Yu Meng 2011). This evaluation is 
dependent on the relative orientation of the ligand's atoms with respect to those forming the 
protein active site. In a docking experiment every single conformation of the binding complex is 
referred to as a pose, and each evaluated pose has an associated scoring value. For an 
accurate evaluation of binding energy a synergistic cooperation between two elements is 
needed: i) a scoring function assessing the quality of the interactions, and ii) a pose search 
algorithm that optimize those interactions. Thus, the scoring function is responsible of discern 
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favorable from unfavorable conformations, while the pose search algorithm samples the 
conformational space to optimize the evaluation of the scoring function.  
There are three types of scoring functions: i) force-field-based, ii) empirical and iii) knowledge-
based (Cheng, Li et al. 2012). Force-field-based scoring functions evaluated the binding by 
computing all the non-bonded interactions among the atoms of the binding complex. The van 
der Waals interactions are represented by Leonard-Jones potentials, while the electrostatic 
contributions are computed from a Coulombic perspective, using a distance dependent 
dielectric function. The empirical scoring functions assess the binding affinity by a weighted sum 
of energy terms such as hydrogen bond, ionic interaction, hydrophobic effect and binding 
entropy. The weights scale the contribution that each term provides to the final score and are 
calibrated to reproduce the experimental binding affinities from a set of known complexes. The 
knowledge-based scoring functions use distance dependent potentials between each pair of 
atoms of the protein-ligand complex. These potentials are calibrated based on the statistical 
analysis of X-ray crystal structures complexes. The rationale behind this approach is that the 
more frequent an interacting pair is found in crystal complexes, the more favored is its 
interaction.  
The pose search algorithms are very diverse, thus here are briefly described three of the most 
commonly used (Xuan-Yu Meng 2011): i) incremental construction methods, ii) Monte Carlo 
methods and iii) Genetic methods. In the incremental construction methods, the ligand is firstly 
divided into fragments. Secondly, each of these fragments is positioned in to the active site in a 
sequential fashion. Fragments are usually defined by rotatable bonds and the largest fragment 
referred to as anchor fragment is docked first. After the anchor fragment is positioned, it 
becomes a fixed part of the active site and the next fragment is docked. This process is 
continued until all the fragments are being docked and the original molecule can be 
reconstructed. This methodology is used in DOCK 4.0 (Moustakas, Lang et al. 2006), FlexX 
(Gastreich, Lilienthal et al. 2006), and eHiTS (Zsoldos, Reid et al. 2007). In the Monte Carlo 
methods, the protein-ligand poses are generated by sampling the configuration space of the 
rigid-body translations and rotations, in addition to the sampling of rotatable bonds. The pose 
selection is made obeying an energy based criterion. If the current pose satisfies the criteria, the 
pose is first stored and then modified to generate the next conformation. Monte Carlo sampling 
methods are used ICM (Neves, Totrov et al. 2012) and RosettaLigand (Combs, DeLuca et al. 
2013). In Genetic methods each pose is described by a set of genes, each of them encoding a 
particular state the ligand´s degrees of freedom. Several poses, conforming a “generation” or 
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“set of individuals”, are evaluated and compared among each other. The individuals with better 
evaluations are then chosen to perform on them “gene mutations” that render the next 
generation. Genetic algorithms are used in AutoDock (Morris, Huey et al. 2009) and GOLD 
(Verdonk, Cole et al. 2003).  
Regardless of the scoring function and pose search algorithm, a typical output from docking a 
single molecule in the active site is composed by a small set of the best scored poses. Although 
in principle these suggested poses are ranked by its scoring values, inaccuracies of the scoring 
functions make necessary the performance of a visual inspection of the suggested poses in 
order to identify false positives. This visual analysis is crucial in the success of a docking 
experiment (Klebe 2006; Cosconati, Forli et al. 2010; Broccatelli and Brown 2014).  
 
2.1.2 Virtual Screening workflow 
Several considerations are needed in a traditional structure-based VS work flow (Figure 1). 
Firstly, a decision needs to be made in regard of the active site model to be used: single 
structure or a set of structures, experimental data or modeling data, etc. The influence that the 
active site conformation has on the identification of active molecules is well documented (Sinko, 
Lindert et al. 2013). Secondly, the preparation of the screening library usually requires a pre-
filtering of molecules that form the library (Lipinski, Lombardo et al. 2001). Removing molecules 
that have a low probability to result as actives, for example by looking at a specific 
physicochemical property, reduces considerably the computation time, eases the analysis and 
increases the chances of finding an active molecule. After the preparation of the active site and 
the chemical library, the VS consist in docking each molecule of the library into the active site. 
As described in the previous section, form each molecule (𝑀)  a set of docking poses is 
generated 
𝑀(𝑃𝑜𝑠𝑒𝑘  ,𝑆𝑐𝑜𝑟𝑒𝑘  )    𝑤ℎ𝑒𝑟𝑒   𝑀 ∈  𝑆𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 𝐿𝑖𝑏𝑟𝑎𝑟𝑦 ;    𝑘 ∈ 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑜𝑐𝑘𝑖𝑛𝑔 𝑝𝑜𝑠𝑒𝑠  
Moreover, if docking is performed on a set of protein structures, then of each molecule (𝑀) 
𝑀�𝑃𝑜𝑠𝑒𝑘  ,𝑆𝑐𝑜𝑟𝑒𝑘 ,𝑅𝑒𝑐𝑒𝑝𝑡𝑜𝑟𝑗�   𝑤ℎ𝑒𝑟𝑒 𝑅𝑒𝑐𝑒𝑝𝑡𝑜𝑟𝑗  ∈ 𝑆𝑒𝑡 𝑜𝑓 𝑎𝑐𝑡𝑖𝑣𝑒 𝑠𝑖𝑡𝑒𝑠   
From this perspective, the visual inspection of all possess is no longer feasible, even for a few 
hundreds of screened molecules, thereby the use of the docking scoring value as a main 
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ranking method imperative. Identifying the actual binding mode based on the docking score 
from a set of poses of the same ligand is now a days considered as a partially solved problem 
(Damm-Ganamet, Smith et al. 2013). However, far more challenging is the comparison of poses 
between different ligands. The difficulties emerge, for example, in that conformational entropies 




Figure 1. Virtual Screening Workflow in a structure-based approach.  
Several methods and tools have been proposed to produce an automatic and reliable ranking of 
the docked library (Fukunishi 2010), nevertheless the problems is still far from being solved 
(Damm-Ganamet, Smith et al. 2013). The appropriate treatment of all these issues in the VS 




2.2 20S proteasome  
2.2.1 Biological Role and Structure 
90% of all the non-lysosmal protein cleavage that takes place in the cell is performed through a 
protein degradation pathway, known as Ubiquitin Proteasome System (UPS) (Hershko and 
Ciechanover 1998). In order to maintain this process strictly regulated, target proteins for 
degradation are tagged with a polyubiquitin chain that is subsequently recognized by the heart 
of this degradation pathway, the 26S proteasome(Pickart 2004). 
 
Figure 2. Protein degradation through the UPS. Proteins that need to be degraded are marked 
with a poli-ubiquitin chain. This attachment is an ATP dependent process that involves the 
action the enzymes E1-E3 (not shown in the scheme for clarity reasons). This ubiquitination is 
the signal recognized by the regulatory particle 19S to allow the protein to reach the inner part 
of the 20S, where the active subunits will cleave the protein into peptides. These peptides can 
be cleaved further by other peptidases or used as antigens in an immune response.  
 
The 26S proteasome is composed by two major substructures: the 19S Regulatory Particle (RP) 
and 20S proteasome Core Particle (CP). The RP, has been shown to be situated in one or two 
ends of the barrel-shaped structure of the 20S CP, and has the function of recognizing and 
unfolding poly-ubiquitinated proteins and subsequently translocating them into the catalytic 
lumen this macromolecule, known as the 20S (Figure 2). The 20S proteasome has a barrel-like-
shaped structure given by four stacked heptameric rings in α-β-β-α stoichiometry. In eukaryotes 
seven different α- and β-subunits form the ring structure, whereas in simpler organisms, such as 
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archeabacteria, just one type of α- and β- subunits conform the heptameric arrangement. In the 
case of eukaryotic proteasome the catalytic centers of the CP are located inside the β-subunit 
rings, specifically at subunits β1, β2 and β5. After the peptidolityc activity has occurred in these 
sites the peptides leave the 20S and are further cleavage by other peptidases. However, 
alternatively, the peptides may reach the major histocompatibility complex (MHC) class I. In this 
scenario the peptides form part of an adaptive immune response (occurring in vertebrates) 
(Figure 2). To facilitate the recognition by the MHC I, antigenic peptides need to have a 
hydrophobic residues at their C-terminal (Strehl, Textoris-Taube et al. 2008). To effectively 
produce peptides with the proper characteristics, the constitutive actives subunits, β1, β2 and 
β5, are substituted by immuno counterparts, β1i, β2i and β5i. Despite high degree of sequence 
similarity, biochemical and cellular assay have shown that the 20S form with the immuno 
subunits (immunoproteasome) has an increased peptidolytic activity with respect to constitutive 
proteasome (Sijts, Ruppert et al. 2000).  
2.2.2 Cleavage mechanism and its inhibition 
From the seven different β-subunits found in CP of eukaryotes, just three are proteolytically 
active; β1, β2 and β5. These active subunits differ from the rest in that they have eliminated a 
pro-peptide from their N-terminal structure, leaving exposed a Threonine, Thr1, which itself 
defines the core of the catalytic triad. Surrounding the Threonine are different specificity pockets 
(S) numbered in relation with their position from the hydrolyzable peptide bond, the 
corresponding side of the peptide substrate (P) are numbered consecuently (Figure 3A). In 20S 
proteasome of eukaryotic, the sequence diversity of the subunits confers structural variation to 
the three active sites given rise to different substrate affinities. These specificities have been 
characterized as caspase-, trypsin- and chymotripsyn-like, for the subunits β1, β2 and β5, 
respectively (Nussbaum, Dick et al. 1998). Structural and mutational analyses have shown that 
residues forming the S1 pocket, and in particular the residue at the sequence position 45 of the 
β active subunit, has a preponderant role in the definition of these specificities (Groll, Bochtler et 
al. 2005).  In the subunit β1 the Arg45 provides to the pocket an acidic nature, while the Gly45 
in the β2 and Met45 in the β5 render basic and hydrophobic milieus, respectively. Nevertheless, 
all three active subunits share a common cleavage mechanism (Groll and Huber 2004). First, 
the Thr1O𝛾 is attached to the carbonyl carbon at the peptide bond of the substrate forming an 
acyl-ester intermediate (Figure 3B). In a second reaction step, Thr1N atom accomplish a proton 
acceptor role, thus promoting the cleavage of the intermediate (Figure 3C). During the catalysis, 
the presence of a water molecule in the proximity of the Thr1 accomplishing a nucleophilic 
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function result crucial, since it not only acts as proton shuttle between Thr1Oγ and ThrN, but 
also participates in the acyl-ester bond disruption of the intermediate.  
 
Figure 3. Cleavage mechanism of the CP. (a) Schematic representation of non-primed substrate 
binding pockets S1, S2, S3…Sn (coloured black except for S2 (grey) due to its lack of presence 
in constitutive CPs) and primed S1’, S2’, S3’… Sn’ sites, depending on their location to the 
peptide bond. Ligand side chains with the proteasomal specificity pockets, are referred to as P1, 
P2, P3…Pn and P1’, P2’, P3’…Pn’, accordingly. (b) Cleavage mechanism by Thr1 in the active 
β subunits of the 20S proteasome ( Figure taken form (Gallastegui de la Rosa 2012) ).  
 
Participation of the CP 20S proteasome in crucial processes of the cellular cycle is well 
acknowledged (Glickman and Ciechanover 2002). Similarly well recognized is its participation in 
the development of main human diseases such as Alzheimer´s disease, autoimmune diseases, 
muscle atrophy and different cancer, e.g. multiple myeloma (Kisselev and Goldberg 2001). 
Consequently copious efforts have been made to develop inhibitors of the 20S proteasome 
activity. Dozens of proteasome inhibitors are currently found in the literature (Beck, Dubiella et 
al. 2012; Kisselev, van der Linden et al. 2012), and can be classified under two schemes: i) 
peptidic or non-peptidic and ii) covalent or non-covalent inhibitors. In the first classification, the 
number of proteasome inhibitors having a peptide-like structure is clearly superior to the number 
of non-peptidic, whereas in the second classification the covalent proteasome inhibitors are 
more numerous than the non-covalent. This testifies that landscape of proteasome inhibitors in 
dominated by covalent peptidic molecules. 
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The 20S proteasome inhibition by covalent peptidic molecules has three components: i) the 
allocation of the peptide side chains into the specificity pockets, ii) the formation of an 
antiparallel β-sheet at the actives site, and iii) the covalent bond formation. The side chains of 
the peptidic inhibitor module the binding at the different catalytic subunits, with P1-site being the 
main contributor. Nonetheless, it is well documented that the residue at P3 has also strong 
influence modulating the peptide binding (Rydzewski, Burrill et al. 2006). The formation of the 
antiparralel β-sheet is a process occurring in all three active sites, since the peptidic inhibitor 
mimics the backbone hydrogens bonds that the peptide substrates originally undertake. Finally, 
the covalent bond formation is highly dependent on the inhibitor head group (the milieu of the 
different active sites also play a role). The head group defines properties as kinetics and 
specificities. Some examples of head groups inhibiting the 20S proteasome are Aldehydes, 
boronic acids and epoxyketones. 
Peptidic aldehydes were the first discovered CP 20S proteasome synthetic inhibitors 
(Borissenko and Groll 2007). The X-ray crystal structures of yeast CP with complexed structures 
of Calpain inhibitor I and II (CAL I and CAL II) aided to unveil the cleavage as well as the 
inhibitory mechanism by the proteasome reacts, demonstrating the key role played by residue 
Thr1. The inhibition of CAL I is accomplished by the formation of a hemiacetal bond between 
the aldehyde group and the Thr1 (Kisselev and Goldberg 2001). The main disadvantage of the 
aldehyde inhibitors is their lack specificity proteasome as they also react with serine and 
cysteine proteases.  
Peptidic boronic acids are probably the most successful proteasome inhibitors (Pellom ST Jr. 
2012). They offer a set of advantages over their aldehyde counterparts: i) low specificity towards 
other proteases, ii) low dissociation rate from 20S proteasome and iii) higher inhibitory activity. 
A peptidic boronic acid molecule (Bortezomib) is since 2003 approved by the Food and Drug 
Administration (FDA) as drug against multiple myeloma. Nonetheless, peptide boronotes still 
present unwanted side effects as a consequence of their slow reversibility (Ruschak, Slassi et 
al. 2011). 
Peptidic epoxyketones, such as epoxomycin derived from an actinomycete strain, possess a 
high specificity towards the chymotrypsin-like active site, although inhibition effects on the other 
two active subunits are also observed (Meng, Mohan et al. 1999). Epoxyketons binds 
irreversibly to the Thr1 by forming a morpholino ring with the Thr1Oγ and ThrN. This peculiar 
moiety, form upon binding, renders epoxyketones highly specific towards the 20S proteasome, 
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since Thr1 is not present at the aminoterminal postion in other proteases. Carfilzomib, an 
epoxomycin analogue, is since July 2012 an approved drug by the FDA to treat multiple 
myeloma (Steele 2013). However, Carfilzomib, as Bortezomib, is unable to penetrate solid 
tumors (Stein, Cui et al. 2014).  
Despite of the success of the covalent peptidic inhibitors in the clinical field there is place for 
improvement. Form a medicinal chemistry perspective, covalent inhibitors are usually avoided 
due to the risk their overreactivity and therefore possible secondary effects (Zhou, Chan et al. 
2005). Peptidic inhibitors, on the other hand, present a series of drawback such as poor 
metabolic stability, poor membrane permeability and poor oral bioavailability (Craik, Fairlie et al. 
2013). In the specific case of the covalent peptidic inhibitor of the 20S proteasome already in 
the drug market, they have shown inhability to target solid tumors, and undesired secondary 
effects (Stein, Cui et al. 2014). This situation calls for development of non-covalent and non-
peptidic molecules. In this regard, there are only few X-ray crystal structures of the 20S 
proteasome in complex with non-covalent inhibitors. These inhibitors are to TMC-95A and its 
derivates, hydroxyurea derivates, and K-7174 a homopiperazine derivate.  
TMC-95A and its derivatives are potent non-covalent proteasome inhibitors isolated from 
Apiospora montagnei (Koguchi 2000). These natural products, although still peptidic, have a 
cyclic structure that provides them a low entropic cost upon binding. TMC-95A is highly specific 
and potent towards the 20S proteasome, it inhibitory activity reaches the nanomolar regime at 
the chymotrysin-like active site and the micromolar range at the other two catalytic centers 
(Koguchi 2000). Despite of these advantages, the cyclic structure of TMC-95A and their 
derivatives represents a complex synthetic challenge that prevents their use for commercial 
purposes. Linear analogs have been made, in order to simplify the chemical synthesis process, 
but a considerably loss in potency has been encounter (Groll, Gallastegui et al. 2010). 
The yeast 20S proteasome in complex with a hydroxyurea compound was the first reported 
structure showing a non-covalent and non-peptidic ligand binding mode (Gallastegui, Beck et al. 
2012). These hydroxyurea inhibitors show specificity for the chymotrypsin-like active site of 
yeast 20S proteasome. Its non-covalent interaction proved to be unique in comparison with 
other inhibitors uncovering two side pockets to S1 and S3 termed the S1’ and the S3’ pockets. 
These inhibitors were optimized leading to a highly potent inhibitor with a Ki value in the 
nanomolar range termed H10. H10 showed to make two strong hydrogen bonds between the 
hydroxyurea moiety and two highly important residues. This inhibitor had two side chains; one 
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located in the S1’ pocket (methyl group) and the second one in the S3’ (the adamantly group). 
Unfortunately, this inhibitor showed poor solubility and cell permeability properties (personal 
communication with the authors).  
K-7174 a homopiperazine derivate is another interesting non-covalent and non-peptidic 
proteasome inhibitor (Kikuchi, Shibayama et al. 2013). This molecule inhibits the all active 
subunits by occupying the primed binding pockets. Due these characteristics, it is able to work 
concomitantly with Bortezomib in the induction of apoptosis in myeloma cells (Kikuchi, Yamada 
et al. 2013) . Promising results are expected from Homopiperazine derivatives that compensate 
for the weak points of the covalent peptidic inhibitors described before.  
It is important to highlight that most of the 20S inhibitors design towards hindering the β5 
subunit activity, which has been identify the essential for the 20S proteasome operation (Parlati, 
Lee et al. 2009). Nevertheless, despite of the high degree of homology, the structural variation 
among subunits of different species, including the immuno variations, render different active 
sites, thus opening the possibilities of achieving specificities among species. For instance, the 
development and design of inhibitors specific for human immunoprotesome is highly desirable 













2.3 Initial virtual screening on the 20S 
The use of Structure-based Virtual Screening offers the possibility of exploring the molecular 
landscape in search of new inhibitors against the 20S proteasome. Here is presented the initial 
steps taken towards the challenging goal that represents the identification of novel proteasome 
inhibitors. It is important to stress that this preliminary results are intentionally presented as part 
of the introduction, since it provided the platform for the development of the research that 
constitutes the main part of this dissertation.  
2.3.1 Reliability score and docking map 
As previously mentioned, two aspects of the structured-based Virtual Screening (VS) have great 
influence on the results: i) Human visual inspection of the docking poses and ii) the model of the 
active site. The visual evaluation of the docking results is crucial in the reduction of false 
positives (Klebe 2006). However, to perform this assessment for a large compound library is 
utterly unreliable, thus calling the development a post-analysis that provides a trustable ranking 
of screened molecules. On the other hand, the dependency of the protein model can be mild by 
using either several active site models or by considering a flexible active site (Sinko, Lindert et 
al. 2013). Given these scenarios, an automated selection a process was devised attempting to 
reduce de number of molecules on which perform the visual evaluation. Due to the vast 
structural information on the β5 subunit, the protocol was performed to work on several crystal 
structures. 
The core idea of the protocol was that within a single screening experiment, i.e., docking of a 
chemical library into a single active site, molecular candidates were selected automatically 
based on a “reliability score”, which tries to capture important aspects that would render a 
docked molecule worth to evaluate visually. The reliability score was computed as the weighted 
sum of values derived from the virtual experiment: i) average of high scored poses, ii) rmsd 
among the poses, and iii) number of poses in the top half of the rank comprised by whole 
screened library,  
𝑟𝑒𝑙𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑠𝑐𝑜𝑟𝑒 = 𝑊𝐷𝑠𝑐𝑜𝑟𝑒𝐷𝑆𝑐𝑜𝑟𝑒 + 𝑊𝑟𝑚𝑠𝑑𝑅𝑚𝑠𝑑 +  𝑊𝐹𝑟𝑒𝑞𝐹𝑟𝑒𝑞 
Only molecules satisfying these cut-off values were selected as candidates and their reliability 
score was computed. Since the docking performance of the molecule depends on the protein 
crystal structure, each model of the active site had its own set of candidates. The performance 
of all these molecules over the whole set of protein structures was depicted in a “Docking Map” 
13 
 
(Figure 4) with idea to provide a fast visual way to identify if a molecule has a preference for a 
certain set of structures. 
Figure 4. Docking map algorithm for virtual screening. A) Each molecule in the chemical library 
is docked in each structure of the ensemble. B) For each structure, the molecules are evaluated 
by the “reliability score”. C) The a set of candidate molecules are reported in docking map 
scheme, where the performance each candidate molecule on ensemble of protein structures is 
shown. 
 
2.3.2 Initial test 
The “Docking Map” was tested on a library of 3000 purchasable compounds containing a 
hydroxyurea-like scaffold. This library was docked into an ensemble constituted by yeast and 
mouse constitutive as well as the mouse immuno proteasome structures. The objective of the 
test was to evaluate the capacity of the algorithm to provide a fast visual evaluation on whether 
a molecule has preference for certain set of structures and to reduce the amount of molecules 
on which to perform human evaluation. From the screening of the 3000 compounds (first 
library), a very noisy map was obtained, although some interesting features were observed 
(Figure 5A). For example, molecules from 5 to 8 showed a very promiscuous binding by scoring 
relatively good in all the active site structures. In contrast, candidate molecules 9 and 10 
showed preference for a sub-set of the yeast structures, thus indicating presence of conserved 
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structural difference among yeast active sites. The candidate molecule 1 generated particular 
interest, since it showed slightly more preference for the iCP structures than to the cCP. To test 
whether additional molecules resembling molecule 1 could enhance this signal, 200 new 
molecules were included in the analysis. These molecules were selected from online databases 
satisfying the condition to be at least 0.7 similar to candidate molecule 1 in the tanimoto scale. 
With this enriched library (second library) the specificity signal increased in intensity for just one 
molecule (Figure 5A). Interestingly, this new molecule (candidate molecule number 1 in the 2nd 
screening) showed a very similar scaffold to some molecules of the first screening (Figure 5B). 
Based on the visual inspection of these molecules docking poses a new set of 50 molecules 
was manually created and included in the analysis (third library). The docking of this new set of 
molecules produced an outstanding result in their preference towards the mouse immune 
proteasome (Figure 5A), especially candidate molecule number 7.  
Figure 5. Testing of the Docking Map algorithm. A) Docking maps computed from virtual 
screening data from three chemical libraries referred in the text. B) Examples of the molecules 
showing an interesting docking performance in accordance with the docking map.  
 
Despite of the interesting results indicating the possible identification of a set of molecules with 
a clear preference for the immunoproteasome, it was decided to test experimentally the 
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candidate molecules for the yeast system. This decision was taken due to the complicated 
procedure that is required to purify and crystalize the mouse immunoproteasome, and the more 
economical screening system established for yeast proteasome in our collaborators laboratory, 
Prof. Groll. From results based only on yeast proteasome, 9 of the suggested molecules were 
acquired and tested in a flouromentric assay (Philipp Beck, Prof. Groll lab.). Interestingly within 
this small set of compounds 2 molecules were able to provide a weak inhibition at β5 active site 
(Figure 5). However, their crystallization did not show any electron density. 
 
Figure 6. Testing of commercial molecules on yeast 20S proteasome. A) Compounds bought 
directly from chemical providers were tested on fluorometric assay on yeas 20S proteasome. B)  
The two molecules showing some inhibitory activity (approx. IC50 150μM) show a similar 









 2.3.3 Conclusions from the initial test 
Several conclusions are drawn from this first attempt to perform Virtual High Throughput 
Screening on 20S proteasome.  
• Despite of the lack of electron density in the crystallization of the weak active molecules, 
their identification by structured-based virtual screening resulted quite promising, 
considering that two out of nine tested molecules show weak activity. In addition these 
molecules shared a common chemical feature, thereby offering inhibitor design 
possibilities. 
• The “Docking Map” algorithm provided evidence on the existence of structural features in 
the ensemble of β5 subunits that made possible to distinguish between proteasome 
types, constitutive, immune, yeast and ,even, among different yeast structures. 
• The “reliability score” proved to be an interesting concept that was worth to develop 
further, for example by providing an adequate parameterization of the weighting factors. 
From the perspective provided by these conclusions, it was clear that to increase the certainty 
of the Virtual Screening results on 20S proteasome two main aspects needed to be addressed: 
• A deeper understanding of the structural differences among the different proteasome 
species in imperative, since despite of the high similarity the subtle differences among 
them are utterly crucial for the structured-based Virtual Screening purposes.  
• A refinement of the “reliability score” idea as post-analysis method for Virtual Screening 
experiments needed to be formulated. This refined methodology should be rigorously 
benchmarked against broad spectrum of protein targets.  
These two aspects motivated the work developed on two peer-review publications presented in 







3.1 AutoDock4.2  
AutoDock4.2 uses semi-empirical scoring function to estimate the energy difference (∆𝐺 ) 
between the unbound and bound states of the protein-ligand complex (Huey, Morris et al. 2007). 
∆𝐺 =  �𝑉𝑏𝑜𝑢𝑛𝑑𝑃 𝑖𝑛𝑡𝑟𝑎 − 𝑉𝑢𝑛𝑏𝑜𝑢𝑛𝑑𝑃 𝑖𝑛𝑡𝑟𝑎 �+ �𝑉𝑏𝑜𝑢𝑛𝑑𝑃−𝐿 − 𝑉𝑢𝑛𝑏𝑜𝑢𝑛𝑑𝑃−𝐿 + ∆𝑆𝑐𝑜𝑛𝑓� 
Where ∆𝑆𝑐𝑜𝑛𝑓 is an entropy approximation penalizing the restriction of rotatable bonds upon 
binding and the potentials (𝑉) are computed from the pair wise interaction of atoms within the 
protein (𝑃 𝑖𝑛𝑡𝑟𝑎) and between the protein-ligand complex (𝑃 − 𝐿). The potentials take the form: 
𝑉 =  𝑊𝑣𝑑𝑤��𝐴𝑖𝑗𝑟𝑖𝑗12 − 𝐵𝑖𝑗𝑟𝑖𝑗6 �𝑖,𝑗 +  𝑊𝐻𝑏𝑜𝑛𝑑�𝐸(𝑡)�𝐶𝑖𝑗𝑟𝑖𝑗12 − 𝐷𝑖𝑗𝑟𝑖𝑗10�𝑖,𝑗










The weights (𝑊) are calibrated to fit experimental binding constants. The first term accounts for 
attraction/repulsion interactions. The second term evaluates the hydrogen bond interactions 
based on distance (𝑟𝑖𝑗 ) and directionality (𝐸(𝑡)). The third term accounts the electrostatic 
interaction using a columbic potential. The fourth term is the desolvation potential based on the 
volume of atoms (𝑣) that surround a given atom and shelter it from the solvent. This interaction 
is weighted (𝑆 ) and decays exponentially  (𝜎 = 3.5 Å). The pose search is performed by a 
genetic algorithm under a Lamarckian scheme.  
 
3.2 AutoDock Vina  
In AutoDock Vina the scoring function is combination of knowledge-based potentials and 
empirical scoring functions (Trott and Olson 2010). The conformation is evaluated (𝐶 ) by 
accounting interactions intra and inter the molecules 
𝐶 = 𝐶𝑖𝑛𝑡𝑒𝑟 + 𝐶𝑖𝑛𝑡𝑟𝑎 
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The summations run over all pair of atoms (i,j), excluding atoms separated by three consecutive 
covalent bonds (1-4 interactions). The interactions are defined in terms of the surface distance 
𝑑𝑖𝑗 = (𝑟𝑖𝑗 − 𝐴𝑡𝑜𝑚𝑖𝑐 𝑟𝑎𝑑𝑖𝑢𝑠𝑖 −  𝐴𝑡𝑜𝑚𝑖𝑐 𝑟𝑎𝑑𝑖𝑢𝑠𝑗) ∗ (1Å)−1 and have associated a weight (𝑊) 
𝐶 =  𝑊𝑔𝑎𝑢𝑠𝑠1�𝑒�−𝑑𝑖𝑗 0.5� �2
𝑖<𝑗
+ 𝑊𝑔𝑎𝑢𝑠𝑠2�𝑒⎝⎜⎛−�𝑑𝑖𝑗−3� 2� ⎠⎟⎞
2






⎧                1 ,             𝑖𝑓        𝑑𝑖𝑗 < 0.5                0 ,            𝑖𝑓         𝑑𝑖𝑗 > 1.5






          1 , 𝑖𝑓           𝑑𝑖𝑗 < −0.7                  0 , 𝑖𝑓           𝑑𝑖𝑗  >    0           
𝑑𝑖𝑗
−0.7 ,             𝑜𝑡ℎ𝑒𝑟 𝑤𝑖𝑠𝑒             𝑖<𝑗𝑖𝑓 𝑎𝑝𝑝𝑙𝑖𝑒𝑠  
Note the last two terms are applicable only for the appropriate pair of atoms, whereas the steric 
terms (the first three terms) consider all atom pairs. The pose search algorithm used by 
Autodock Vina is an Iterated Local Search global optimizer adapting a Broyden-Fletcher-
Goldfarb-Shanno (BFGS) method for the local optimization. 
 
3.3 Rosetta Ligand  
The all-atom scoring function in Rosetta comprises weighted individual terms that are summed 
to create an estimation of the total energy (Combs, DeLuca et al. 2013). Most of these terms are 
knowledge-based potentials. The van der Waal interactions are represented by a 6–12 Lennard-
Jones potential with attractive and repulsive terms. The solvation energy is modeled by an 
implicit water scheme where the burial of polar atoms is penalized. The electrostatic interactions 
are modeled by the scoring function contains Newtonian physics–based terms, including a 6–12 
Lennard-Jones and a solvation potentials. The 6–12 Lennard-Jones potential is split into 
attractive and repulsive terms, and represents the van der Waals interactions. The solvation 
potential is an implicit water model that penalizes the burial of polar atoms. The electrostatic 
interactions are captured through a pair potential, and a hydrogen bond potential that accounts 
for long-range and short-range, as well as, directionality hydrogen bonding. Additionally, the 
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scoring function has rotametic terms that dictate side chain conformations according to the 
Dunbrack rotamer library.  
 
3.4 Molecular Dynamic Simulations (Gromacs) 
In a system of N interacting atoms, for example a protein solvated in water, molecular dynamics 
(MD) simulation allow to evaluate dynamical properties of that system by solving Newton´s 
equation of motion (D. van der Spoel, E. Lindahl et al. 2010). With each atom having a 
coordinate (𝒓𝑖), usually provided by X-ray structures, an atomic mass (𝑚𝑖), provided by the atom 
type, and a velocity, usually randomly assigned according to the Boltzmann distribution, the 
system of equations to solve is: 
𝜕2𝒓𝑖
𝜕𝑡2
 = 𝑭𝒊, 𝑖 = 1, … ,𝑁 
With the forces 𝑭𝒊   being the negative derivate of a potential function 𝑉 that defines the 
interactions among the particles 
𝑭𝒊 =  − 𝜕𝑉𝜕𝒓𝒊 
Any other properties specific to each atom in the system are considered to be within the 
potential function 𝑉. Additionally note that 𝑭𝒊  and 𝒓𝒊  are vectors.  
This system of equations is solved in small time steps, thus providing a time evolution of the 
system of 𝑵 interaction atoms that is recorded in a set of individual frames, the trajectory of the 
system. There are several thermostats and barostats that, in principle, allow the simulation to 
generate conformations according to the canonical (NVT) and isothermal-isobaric (NPT) 
ensembles. The terms in the potential function can be classified in three categories: i) non-
bonded, ii) bonded and iii) restrains. The non-bonded interactions are pair-wise additive and 
centro-symmetric. They contain repulsion and dispersion terms in the form of Leonard-Jones 
potentials (6-12 interaction) together with a columbic interaction, which is computed from the 
assignment of partial charges to the atoms. The bonded interactions contains terms that 
consider bond lengths, bond angles and dihedral angles, thus involving interactions between 
two, three and four atoms, respectively. While the non-bonded and bonded interactions attempt 
to capture the effects of the electron clouds, thus representing real interactions, the restrains 
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terms in the potential (which are optional to include) represent fictitious interactions that impose 
motion restrictions on the system, either to avoid disastrous deviations, or to include knowledge 
from experimental data.   
 
3.5 Principal Component Analysis 
The principal component analysis (PCA) is a multivariate statistical tool that allows the reduction 
of high-dimensional data sets onto a group of collective variables. PCA has been successfully 
applied to extract collective modes of motion in proteins from molecular dynamics simulation 
trajectories (Kitao, Hirata et al. 1991; García 1992). To study the protein motion of a protein, an 
ensemble of structures, taken from a molecular dynamic simulation trajectory or from as set of 
experimental structures, is averaged to generate a reference structure. Every single frame is 
then compared against the average structure to generate a co-variance matrix, which is also 
averaged over the whole ensemble. 
𝐶𝑖𝑗 = 〈( 𝑥𝑖 − 〈𝑥𝑖〉 )� 𝑥𝑗 − 〈𝑥𝑗〉 �〉 
Thus, the matrix elements 𝐶𝑖𝑗  contain averaged information of the correlated atomic 
displacements, 𝑥𝑖 and𝑥𝑗, with respect to their average positions, 〈𝑥𝑖〉  and 〈𝑥𝑗〉. By diagonalazing  
𝐶 this correlated motions can be represented by a set of orthogonal vectors that dissect the 
global displacements. This diagonalization is solved as an eigenvalue problem  
𝐴𝑡𝐶𝐴 = 𝜆 
The eigenvectors are represented by the matrix𝐴 , and the column vector 𝜆  contains the 
corresponding eigenvalues. The larger the eigenvalue the larger the movement described by 
the associated eigenvector. Usually only first few eingenvectors are needed to capture the most 
relevant domain displacements.  
 
3.6 Artificial Neural Networks 
An Artificial Neural Network (ANN) is a machine learning model inspired by the operation 
process observed in biological neural networks (Bishop 2006; Jalali-Heravi 2008). This 
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computational model is formed by artificial neurons, also referred to as nodes, organized in a 
set of hierarchical layers, each layer constituted by a certain number of nodes. The nodes of 
different layers are connected between them for signal transmission. The outputs of the nodes 
in a given layer become the inputs of the nodes in the subsequent layer. The connections are 
weighting factors that scale the input received by each node, thus affecting the output signal 
that is going to be propagated to the nodes of the next layer (Figure 7A).  
 
Figure 7. Typical organization of an Artificial Neural Network (ANN) trained under a 
backpropagation protocol. A) ANN connectivity. The scheme shows a three layer network: input 
layer consisting of D number of nodes, hidden layer with M nodes and output layer constituted 
by k nodes. The nodes and the weighted connections are represented by circles and lines, 
respectively. In sake of clearance, only some connection weights are labeled. The superscripts 
(h) and (o) are used to differentiate the weights from the hidden and output layers, respectively. 
In the hidden layer there is an extra bias node that contributes in the transition of signal to the 
output layer. B) Training with backpropagation. After the set of inputs are analyzed by the ANN, 
the difference between the ANN´s output and the expected value is computed and used to 
modify the weights of the network. This error estimation is an iterative process that is used to 
adjust the performance of the network.  
 
As a machine learning algorithm, the ANN needs to be trained before it can be used for 
prediction purposes. In one of the most popular trainings, the backpropagation algorithm, the 
ANN is trained by providing examples of the result expected given certain inputs were provided. 
A typical architecture of a ANN with a backpropagation training consists of three layers: i) input 
layer dealing with the input data directly, ii) a hidden layer taking information from the input layer 
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and sending its own output to next layer, ii) and output layer which returns values that can be 
evaluated with respect to of the expected results. The signal processing within each node is 
defined as the sum of the weighted input signals  
𝑎𝑗 =  �𝑤𝑖𝑗𝑥𝑖 + 𝑤𝑗0𝐷
𝑖=1
 
The quantities 𝑎𝑗  are linear combinations of the input values (D input values in this case) 
reaching the node j plus an additional bias term 𝑤𝑗0 (optional). The 𝑎𝑗 values, also known as 
activation values, are then transformed into a single output using a differentiable and nonlinear 
activation function 
𝑧𝑗 = ℎ�𝑎𝑗� 
This output value (𝑧𝑗) becomes the input that is transmitted to the next layer of nodes (feed-
forward architecture). Common functional forms of ℎ(∙)  are either a logistic sigmoid function 
𝑧𝑗 =  11 + 𝑒−𝑎𝑗 
or a softmax activation function 
𝑧𝑗 = 𝑒𝑎𝑗∑ 𝑒𝑎𝑖𝐷𝑖  
The 𝑘 output values of the ANN (𝑦) are compared against a set of  𝑘 target values in terms of a 
squared difference over 𝑝 training patterns 
𝐸 = 12���𝑦𝑝𝑘 − 𝑡𝑝𝑘�2
𝑘𝑝
  
The target values are an essential part of the training process. In back-propagation learning, the 
error in prediction is used to adjust the weights in order to minimize the error of the next iteration 
(Fig 7B) 
∆𝑤𝑖𝑗(𝑛)  =  𝜂𝛿𝑖𝛰𝑗 + 𝛼∆𝑤𝑖𝑗(𝑛 − 1) 
Where ∆𝑤𝑖𝑗 represents the change in the weight factor for each network node, 𝛿𝑖 is the error 
associated with the node i and 𝛰𝑗 is the output value of the node j. The learning rate (𝜂) and 
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momentum factor (𝛼) are parameters that need to be optimized before the training, since they 
control the velocity and the efficiency of the learning process. Similarly, the number of nodes 
forming the hidden layer also affects the training of the network. Too many hidden nodes can 
cause overtraining, thus making the ANN useless for predictions besides the training set, and 
too few can render the network unable to learn. After training the ANN to a satisfactory level, the 





















4. Description of the first publication  
Differential global structural changes in the core particle of the yeast and mouse proteasome 
induced by ligand binding by Marcelino Arciniega, Philip Beck, Oliver F. Lange, Michael Groll 
and Robert Huber. (Marcelino Arciniega contributed in: research design, performing the research, data 
analysis, writing the paper) 
The vast amount of X-ray crystal structures of the 20S proteasome in complex with small 
molecule inhibitors, mainly on the β5 subunit of yeast protesome, proved the need of detailed 
analysis of these structures to select appropriate models for developing structured-based virtual 
screening. The influence that the active model has on the virtual screening results was 
experienced by first hand on the “Docking map” analysis described in the introduction of this 
dissertation. The initial idea was to generate a classification of the known crystal structures of 
the β5 subunit of yeast 20S proteasome, and based on this classification identify the set of 
complexes that best represented the structural plasticity of this active site. Thus this clustering 
problem was approached using Principal Component Analysis (PCA).  
Interesting results were obtained when PCA was applied, on the backbone atoms, of the β5 
ensemble of the yeast structures. The PCA showed two well defined clusters that correlated 
with the presence or absence of peptidic inhibitor at the active site, thus allowing the 
classification of the structures in pep- and apo-clusters (please notice the apo cluster also 
contained structures in complex with non-peptidic inhibitors). These results were surprising, 
since in 15 years of structural work on inhibitor design for the 20S proteasome, such movement 
has never been described. The only reported backbone movement, induced by a peptidic 
inhibitor, was that of β5 subunit in the mouse constitutive. Interestingly, the analysis of mouse 
β5 constitutive and immunoproteasome structures from the perspective of the yeast ensemble 
revealed that the backbone movement observed in the constitutive mouse proteasome is 
essentially the same than that of the yeast proteasome. The mouse immunoproteasome 
structure appeared, on the other hand, to maintain a structure similar yeast pep-cluster even in 
its apo state. The relevance of the peptidic binding in inducing the backbone movement was 
supported by Molecular Dynamic simulations results and the X-ray crystal structure of a Boc-
(Ala)3-COH inhibitor in complex with the yeast β5 subunit. The implications that this movement 
has on the rest of the subunits of the 20S proteasome were also investigated. From this 
analysis, possible communications pathways between i) the cis and tras β5 subunits and ii) the 
β5 active site and the α-subunits were revealed.  
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5. Description of the second publication  
Reprinted with permission from “M. Arciniega and O. F. Lange. Improvement of Virtual 
Screening Results by Docking Data Feature Analysis. J Chem Inf Model. (2014) 54:1401-11.” 
Copyright 2014 American Chemical Society. (Marcelino Arciniega contributed in: research 
design, performing the research, data analysis, writing the paper) 
 
This work corresponds to the necessity to develop an automated algorithm that allows a better 
selection of compounds in the context of structured-based virtual screening and corresponds to 
the development of the concept of “reliability score” presented in the introduction of this 
dissertation. The idea behind it is to evaluate the docked compounds based on an evaluation of 
a set of features that would render a docked molecule interesting for experimental testing. 
These features, derived from the analysis of their docking data, represent concepts that would 
be considered by a human user as indicators of the molecule´s inhibitory activity. Since the 
relative importance or weight that each of these features would receive from a human user 
depend on his expertise in working with a given docking program, the problem of adjusting such 
weights called the use of a machine learning approach using an Artificial Neural Network (ANN).   
To test this idea, three different docking programs were used on a virtual screening benchmark 
consisting of datasets of ligands and decoys for 40 different proteins. Additionally, a consensus 
approach was established combing information for the three independent docking programs.  
From the data generated by each individual program five docking features were observed on 
each screened molecule: i) best docking score, ii) ligand efficiency, iii) scores from similar 
molecules, iv) the position of the ligand’s poses within the general rank, and v) structural 
consistency of the ligand’s poses. The information associated to each screened molecule was 
used to feed the input layer of an ANN that returned a single value assessing the activity 
chances of a given molecule. The ANN was trained, validated and applied on each the 40 
datasets.  
The virtual screening performance of this approach, called Docking Data Feature Analysis 
(DDFA), was compared to that of the traditional method, which consists in rank the screened 
libraries based only on the docking score. The DDFA methodology outperformed the traditional 
ranking method, achieving substantial improvement. The robustness of the methodology and 
the significance of the improvement were also assessed. When comparing the DDFA 
performance with other methodologies found in the literature, the DDFA results were as good as 




Q:1; 2; 3Differential global structural changes in the core
particle of yeast andQ:4; 5 mouse proteasome induced by
ligandQ:6; 7 binding
Marcelino Arciniegaa,b,1, Philipp Beckb, Oliver F. Langec, Michael Grollb, and Robert Hubera,b,d,e,1
aMax Planck Institut für Biochemie, 82152 Martinsried, Germany;Q:8 bCenter for Integrated Protein Science at the Department Chemie, Lehrstuhl für Biochemie,
Technische Unversität München, 85748 Garching, Germany; cBiomolecular NMR and Munich Center for Integrated Protein Science, Lehrstuhl für Chemie,
Technische Universität München, 85747 Garching, Germany; dZentrum für Medizinische Biotechnologie, Universität Duisburg-Essen, 45117 Essen, Germany;
and eSchool of Biosciences, Cardiff University, Cardiff CF10 3US, Wales, United Kingdom
Contributed by Robert Huber, May 8, 2014 (sent for review April 14, 2014)
Two clusters of configurations of the main proteolytic subunit β5
were identified by principal component analysis of crystal struc-
tures of the yeast proteasome core particle (yCP). The apo-cluster
encompasses unliganded species and complexes with nonpeptidic
ligands, and the pep-cluster comprises complexes with peptidic
ligands. The murine constitutive CP structures conform to the
yeast system, with the apo-form settled in the apo-cluster and
the PR-957 (a peptidic ligand) complex in the pep-cluster. In strik-
ing contrast, the murine immune CP classifies into the pep-cluster
in both the apo and the PR-957–liganded species. The two clusters
differ essentially bymultiple small structural changes and a domain
motion enabling enclosure of the peptidic ligand and formation of
specific hydrogen bonds in the pep-cluster. The immune CP species
is in optimal peptide binding configuration also in its apo form.
This favors productive ligand binding and may help to explain the
generally increased functional activity of the immunoproteasome.
Molecular dynamics simulations of the representative murine spe-
cies are consistent with the experimentally observed configura-
tions. A comparison of all 28 subunits of the unliganded species
with the peptidic liganded forms demonstrates a greatly en-
hanced plasticity of β5 and suggests specific signaling path-
ways to other subunits.
20S proteasome
Among the many factors involved in protein degradationthrough the ubiquitin-proteasome pathway, the core particle
(CP) 20S proteasome plays the key role of the protease com-
ponent. With the regulatory particle (RP), it forms a complex
that selectively degrades ubiquitin-protein conjugates (1, 2). The
CP in eukaryotes is a multisubunit complex composed of four
stacked heptameric rings: two identical outer rings formed by
seven different α subunits and two identical inner rings formed
by seven different β subunits. The α1–7β1–7β1–7α1–7 organization
defines a cylindrical structure (3). The α-rings control substrate
entry into the lumen of the particle, where it is processed at the
peptidolytic active centers, which are located at the inner walls of
the β rings, specifically at subunits β1, β2, and β5. These areQ:11 the
active subunits characterized by an N-terminal Thr residue. The
other four β subunits have unprocessed N-terminal propeptides
and are enzymatically inactive.
All three active subunits share a common peptide hydrolyzing
mechanism with two main steps (4): (i) the positioning of the
substrate peptide in the active site by antiparallel alignment in
between segments 47–49 and 21 of the active β subunits and (ii)
peptide bond cleavage initiated by a nucleophilic attack of the
hydroxyl group of the N-terminal Thr1 on the carbonyl carbon
atom of the scissile peptide. Sequence diversity among β subunits
endows them with distinctive structural features and different
specificity pockets (S1, S2, S3, etc.) where the substrate side
chains (P1, P2, P3, etc.) are bound (5). Consequently, the cor-
relation of structural features of the S1 pockets with the distinctive
cleavage products has led to the association of β1, β2, and β5
with caspase-like, trypsin-like, and chymotrypsin-like activities,
respectively (6).
The catalytically active subunits are substituted in immune
cells of vertebrate organisms by the immune β-subunits β1i, β2i,
and β5i as part of an adaptive immune response. These sub-
stitutions cause substantial functional differences between the
constitutive (cCP) and immuno (iCP) species, reflected in higher
yield of peptides that are recognized by the major histocom-
patibility complex (MHC) class I generated by iCP (7). Addi-
tionally, it has been observed that iCP achieves higher degradation
rates than cCP, in both in vitro and cellular assays (8–13).
Some sequence variations between the constitutive and im-
mune subunits provide explanations to the observed catalytic
differences. Most conspicuously, and first seen in the eukaryotic
proteasome crystal structure from yeast (yCP) (3) and confirmed
by the murine constitutive and immune CP structures (mcCP and
miCP) (14), Arg45 of the β1 subunit, located at the base of the S1
pocket, is replaced by leucine in β1i, thereby causing a specific
change of the electrostatic milieu, in line with the observed low
postacidic activity of the iCP (15).
Despite the high sequence similarity between β5 subunits of
mcCP and miCP including identical active sites, a peptidic
α-β-epoxyketone inhibitor, PR-957, showed higher affinity to iCP
by one order of magnitude. The structural comparison of cCP
Significance
We analyzed 46 molecular structures of the yeast proteasome
core particle (CP) by principal component analysis (PCA) and
discovered two distinct configurations of the principal pro-
teolytic subunit β5: the apo-cluster encompassing complexes
with nonpeptidic ligands and the pep-cluster of complexes
with peptidic ligands. Both configurations differ by a small
domain motion and numerous slight global changes, thus en-
abling intersubunit communication. PCA was expanded to
the mouse CP and revealed a striking difference between the
constitutive CP and the immune CP. The former conforms to the
yeast system and executes the structural change seen in yeast,
although both immune apo and liganded CP classify into the
pep configuration, a possible explanation for the generally
higher activity of the immune proteasome.
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and iCP in their apo and PR-957 liganded states suggested an
explanation. On binding of PR-957, the cCP β5 backbone dis-
plays significant deformations, whereas the iCP β5 backbone
remains unchanged. This observation, together with our experi-
ence in constructing β5 models for virtual screening purposes,
prompted us to reinvestigate the vast amount of structural data
for yCP by a procedure that facilitates discovery of global
changes: principal component analysis (PCA).
We focus our study on the β5 subunit, because β5 inactivation
in yeast renders a lethal phenotype (16) and therefore β5 harbors
an essential enzymatic activity, and because almost all crystallo-
graphically defined complexes are liganded at their β5 active site.
Here we present a detailed investigation of the wealth of yeast
and mouse proteasome ligand complex structures that led us to
embark on structural comparisons beyond the immediate vicinity
of the ligands to obtain a view of the global response of the core
particle of yeast and mouse proteasome to complex formation.
This study (i) is evidence of the structural plasticity of the β,
specifically β5, subunits; (ii) offers novel perspectivesQ:12 for the
analysis of the structure-function relationship of the CP; and (iii)
provides an aid for the design and development of ligands as
drugs for this intensively studied target for cancer and autoim-
mune diseases.
Results
Structural Transition of Subunit β5 on Peptidic Ligand Binding. We
analyzed 46 β5 subunits from yCP crystal structures (yβ5)
reported in the Protein Data Bank (PDB) database (Table S1)
aimingQ:13 to identify backbone transitions induced on inhibitor
binding by PCA because it eases structure classification (17–19).
The projection of each structure onto the first two PCA
eigenvectors revealed two clusters clearly distinguished by the
first principal component (PC1) (Fig. 1). Although PC1 captures
78% of the structural variances, the second principal component
(PC2) accounts for less than 5% (Fig. 1, Inset). The clusters are
highly correlated with inhibitor binding. On the positive x axis,
structures in either the apo-state or in complex with nonpeptidic
inhibitors are found, whereas the projections on the negative side
correspond to structures with peptidic inhibitors. In the follow-
ing, we refer to these clusters as apo- and pep-clusters, re-
spectively. Striking results are obtained by projecting the β5
structures of the murine (mβ5) and bovine (20) (bβ5) species
on the eigenvectors of the PCA analysis of the yeast struc-
tures. The constitutive subunits, mβ5c and bβ5c, are classified
into the apo-cluster in their ligand free forms, whereas the
uncomplexed structure of the immune subunit, mβ5i, coloc-
alizes in the pep-cluster together with the mammalian
liganded structures.
These observations led us to investigate the contribution of the
amino acid side chains of the peptidic inhibitors to the observed
structural perturbation. Thus, we synthesized the peptidic Boc-
(Ala)3-al inhibitor (SI Methods) and determined the yCP coc-
rystal structure with the aim to discern contributions from the
main chain and side chains. The small and neutral methyl groups
do not fill the subsites and are expected to exert minimal in-
fluence. Interestingly, the complex structure clusters with the
pep-series (Fig. 1), thus excluding a decisive role of the side
chains and underpinning the importance of the main chain on
the classifications.
To highlight the domain motion induced by binding of pep-
tidic ligands, structures from each of the two clusters were
overlaid considering residues 1–39 and 125–190 (Fig. 2). The
protein segments containing residues T21, G47, and A49 accept
and donate, respectively, four hydrogen bonds to peptidic
ligands, configuring a short three-stranded antiparallel β-sheet
(Fig. 2A). This appears Q:14to trigger the closure of the binding
pocket relative to the apo-series by shifting the α-helix (H1),
comprising residues 49–70, of yβ5 (Fig. 2B). A similar re-
organization is observed for the mβ5c on binding of a peptidic
inhibitor (Fig. 2C) but is absent in mβ5i, whereas both apo and
liganded structures present a closed conformation to establish
the antiparallel β-structure (Fig. 2D). Similar comparison of apo
and peptidic liganded bacterial proteasomes, using the myco-
bacterial CP structures (21), did not indicate molecular rear-
rangements as seen in yeast.
To support the previous observations on the role of peptidic
binding, we performed a series of molecular dynamics (MD)
simulations of 20 ns length on a truncated model of the CP (SI
Methods). We simulate mβ5c and mβ5i under three different
starting conditions: (i) apo structures, (ii) structures in complex
with a peptidic ligand, and (iii) complexed sctructures but with
the ligand removed. The stability of the open and closed con-
formers is backed up by the simulations (Fig. 3 and Fig. S1).
Notably, projecting the MD trajectories of the apo and the
liganded forms onto PC1, computed from yeast coordinates,
shows that during the simulated time, the structures remain
within their corresponding apo- and pep-cluster regions (Figs. 1
and 3 and Fig. S1). In contrast, deletion of the ligand from mβ5c
and mβ5i impacted the simulation very differently. After 400 ps
(Fig. 3) and 2 ns (Fig. S1) in two independent runs, the mβ5c
shifts from the pep- to the apo-cluster region, remaining there
for the rest of the simulation, whereas mβ5i stays in the pep-
cluster region. Both runs of the MD trajectories sampled regions
that deviate quantitatively from those defined by the PCA
analysis of the yeast structures (Fig. 1), but the histograms reveal
a qualitative agreement and clearly two populations, the apo-
and pep-clusters, respectively. We attribute this quantitative
deviation to the MD equilibration process of the crystal struc-
tures and to the truncated approximation of the CP. Taken to-
gether, the PCA analysis (Fig. 1), the structural overlays (Fig. 2),
and the MD simulations (Fig. 3 and Fig. S1) document that mβ5c
follows the pattern seen in yeast, showing a domain closure on
peptide binding and hydrogen bond formation. Notably this
transition does not occur in mβ5i, where both apo and pep
structures remain in the closed conformation.
Implications of Peptidic Binding on the CP Structure. An identical
PCA analysis for all 14 subunits indicated similar, albeit less
pronounced, clustering only for β4 and β6, which are adjacent
Fig. 1. Projection of the β5 structures on the first two eigenvectors of PCA
(PC1, PC2). Structures of yβ5 (×), mβ5c (□), mβ5i (▽), and bβ5c (△) are
classified into two groups; structures in complexes: (i) peptidic inhibitors
(red) and (ii) nonpeptidic inhibitors or apo structures (black). Filled symbols
indicate structures in complex with PR-957. The Boc-(Ala)3-al yCP complex is
represented by ⊗. The arrows indicate the position of apo (1RYP) and Bor-
tezomib complexed (2F16) structures. (Inset) Eigenvalue spectrum repre-
senting the percentage of the total variance captured by the corresponding
eigenvector.





























































































































to β5 in the heptameric ring. Nonetheless, to further explore
whether the state of the β5 active site has an influence on the rest
of the CP structure, each of the 13 remaining subunits was an-
alyzed from the β5 perspective. For this purpose, the structures
were classified into the apo-cluster, the elements of the β5 pep-
cluster with β5 specific ligands, and the elements of the β5 pep-
cluster with ligands also bound at β1 and/or β2. Average struc-
tures from these three sets were computed, and the differences
for each subunit in their Cα coordinates were mapped along the
polypeptide chain (Fig. 4). In accordance with the PCA data, the
binding of a peptidic inhibitor at β5 induces significant backbone
shifts over the whole subunit. Notably, these are propagated to
the neighboring subunits: β4 and β6, and, to a smaller extent, to
β2. Interestingly, only minor displacements are induced by pep-
tidic binding at β1 and β2. In contrast to the clear perturbations
observed in β subunits, only small and localized signals are ob-
served in the α subunits. The backbone shift in α3 around residue
220 can be associated with the displacements in the β rings.
This isQ:15 supported by a hydrogen bond between α3N221Nγ and
β2D220O, together with the observed displacement of the last 20
residues of β2 that are in close contact with β3 and the shifted
region of β6. Perturbation pathways explaining the other dis-
placements of the α subunits are not evident. Intriguingly, resi-
dues known to be involved in the assembly of the 26S particle
(residue 66 in the α subunits) and located in proximity of the gate
channel (residue 129) are found within the shifted regions. To
assess the effect of peptidic binding from a different perspective,
the crystallographic “temperature” B (disorder) factors of the
main chain atoms were averaged over the same set of structures
as in the Cα analysis (Fig. S2). Interestingly, the analysis shows
that the variations of the B-factors of the β-subunits are sub-
stantially higher than in the α-subunits and follow the trend seen
for the structural alterations on ligation (Fig. 4). Taken together,
the observed variations of Cα positions and B-factors testify to
enhanced structural plasticity of the β subunits, specifically β5,
and mark possible pathways for intersubunit communication.
To gain further insights into possible shift conferment path-
ways, we analyzed Cα differences in β5 (Fig. 5). The shift induced
in β5 propagates to β6 and β2 through the segments 30–41 and
204–212, whereas the transfer to β4 occurs through the segment
115–144. It is worth mentioning that a single β5 subunit interacts
with β4, in both cis and trans, i.e., within its heptameric ring and
across with the adjacent ring, thus enabling communication to
the trans β5. Helix H1 of β5 neighbors α4 and α5 offers a possible
signal pathway to the α rings (Fig. 5B). Interestingly, only minor
influences are observed in β3, despite its proximity to the ligand
binding site of β5. Aside from these observations, at least five
distal segments that are not in direct contact with the active site
depict considerable backbone displacements (Fig. 5A). The role
of these five segments was examined for the definition of an apo-
or pep-structures by a PCA analysis (Fig. 5C). Residues 42–53
produce just enough signal to discriminate among the clusters,
which is expected because most of these amino acids are directly
involved in peptidic binding. However, when residues 30–41 are
considered, a clearer differentiation is observed. This finding is
surprising, because most of them are located at the outer surface
of the CP, thus far from the ligand binding site. Progressive in-
clusion of the other distal segments in the analysis increases the
distance between the clusters, thereby demonstrating that the
signal of peptidic binding propagates to the back of the subunit
and thus describing a possible communication pathway between
the inner and outer surfaces of the CP. The importance of these
segments for peptidic binding at the active site is supported by
Fig. 2. Domain motion in subunit β5 induced by binding of peptidic ligands. (A) Peptidic binding at the active site of yeast β5 (apo in black, liganded in red).
(B) Structural superposition of yβ5 structures: apo (1RYP, black) and complex with a peptidic inhibitor (2F16, Bortezomib, red). (C) Superposition of mβ5c: apo
(3UNE, green) and complex with a peptidic inhibitor (3UNB, PR-957, blue). (D) Superposition of mβ5i: apo (3UNH, green) and complex with a peptidic inhibitor
(3UNF, PR-957, blue). Arrows highlight the domain movement of yβ5 and mβ5c. Ligands are not shown in B–D for clarity.
Fig. 3. Molecular dynamics simulation. Projections of the trajectories of six
mouse β5 structures on PC1 of PCA of the yβ5 structures. The simulated
system corresponds to structures starting from the apo (apo), liganded [pep
(+)] and liganded state after removing the inhibitor [pep(−)]. The solid lines
represent the running averages of 50 frames windows. The histograms on
the right are computed with the raw trajectory data.













































































































































backbone shifts observed in mβ5c (Fig. 5D). Although similar
backbone displacements have been identified in yβ5 and mβ5c,
the mβ5i main chain atoms retain the configuration of the pep-
structure.
Discussion
The regulation of an enzyme activity by ligand binding at an
allosteric, i.e., distant from the active, center is a frequent phe-
nomenon manifested structurally in changes of quarternary
structures as in the founding case of hemoglobin, in large-scale
domain rearrangements, disorder-order transitions, and global
small scale changes. The underlying mechanisms may be a se-
lection from a preexisting population of configurations (confor-
mational selection) or ligand induced structural shifts (induced
fit). An unambiguous distinction between these limiting cases
requires measurement of the kinetics of ligand binding. A
structural definition may be given by the plethora of tools of
structural biology including theoretical and molecular dynamics
calculations, with X-ray crystallography being a main source of
experimental data. However, the detection of small scale global
rearrangements from crystallographic data is challenging when
using the common simple visual inspection of superimposed
atomic models, which are of limited accuracy. PCA has been
introduced and applied to the analysis of conformational
ensembles from molecular dynamics simulations and offers also
a tool for comparing large sets of experimental structures
with the aim of detecting and defining common modes of
deformation (22, 23).
We were inspired to apply this method on the proteasome
crystallographic data for several reasons. In a large set of
structures of yeast CP ligand complexes, no conformational
changes were described, whereas functional activity measure-
ments indicated an allosteric interaction between the different
active sites (24, 25), which should be reflected in structural
changes. However, the interpretations were controversial (26,
27). Additionally, atomic force microscopy (28) and biochemical
assay (29) data suggested a correlation between the status of the
active site at the β-subunits and features of the α-subunits in
yeast CP. In the same line, NMR measurements of the archaeal
20S proteasome indicated an allosteric communication of the
active sites with the α-subunits (30, 31). These observations, to-
gether with the small domain movement seen in the crystal
structures of murine cCP on ligand binding but not in iCP (14),
called for a more detailed analysis.
The reinspection of the multitude of differently liganded yCP
crystal structures provides further insights into the mechanism of
the 20S proteasome. The presented PCA analysis of the yCP was
restricted to main chain atoms and focused essentially on the β5
active subunits. Surprisingly, it revealed two conformers, apo-
and pep-clusters, unveiling differential specific structural
changes on ligand binding and deformations by peptidic ligands
which form, in contrast to other types of ligands, a characteristic
antiparallel β-sheet with the backbone of residues T21, G47, and
A49. We ascribe the wide space drawn out by peptidic ligands in
the PCA map compared with other ligands (Fig. 1) to the large
contact area in their binding pockets, provoking additional dif-
ferential distortions (Fig. S3). Peptidic ligand binding at β5 is the
principal trigger of all observed conformational changes in yCP
and cCP. Additional binding at β1 and β2 has much less influence
on those subunits and on β5 (Fig. 4 and Fig. S4). Covalent
linkage with Thr1 by various reactants of either nonpeptidic or
peptidic ligands does not have a noticeable bearing on the main
chain configurations as defined by PCA analysis. Notably,
mammalian CPs blended into the clusters showing that there is
a consistent structural transformation on peptidic ligand binding
among eukaryotic CPs. The dominant influence of the main
chain ligand protein interaction is revealed by the fact that yβ5 in
complex with Boc-(Ala)3-al clusters with the pep-series. In line
with this finding are the results provided by the MD simulations,
which give support for the existence of two β5 conformations and
highlight the role that peptidic binding has in differentiating
these conformations. Although the apo and liganded structures
of the mβ5c and mβ5i are stable during the simulation time, the
removal of the peptidic ligand from the mβ5c causes a switch
from the pep-conformation to the apo-structure within 400 ps
and 2 ns, respectively, in two runs. In strong contrast and in
agreement with the structural data, removing the peptidic ligand
from the mβ5i structure has no effect.
The tight packing of the subunits in the CP together with the
observed conformational changes opens the possibility of signal
propagation from β5 to other subunits. Most of the conforma-
tional alterations in β5 induced by the peptidic binding are dis-
tant from Thr1 and located at the surface of the CP (Fig. 5A) and
hence are not in contact with other subunits and therefore are
unlikely involved in direct signal transduction. However, they are
evidence for the transit among conformations. Their relevance
for the definition of the apo- and pep-clusters is supported by
PCA and the murine β5 crystal structures (Fig. 5C). Among the
backbone displacements that contact other subunits and may
generate a direct signal, two are preeminent: the backbone shift
induced in both β4 subunits of the segment of residues 115–150
(Fig. 4) and the possible communication with α5 and α4 via the
displacement of α-helix H1.
The conformational effects on the β4 subunits by peptidic
binding at β5 opens a possible allosteric pathway between the β5
subunits. Interestingly, positive cooperativity of the chymotryptic
(β5′s) activity is consistent with this proposal (24, 26, 27, 32).
In regard to the structural rearrangements of α-helix H1, our
observation is also in line with the reported importance of this
helix in the global motions and allosteric communication ob-
served in the archaeal 20S (30) and in the HslV protease (33),
the prokaryotic homolog of the eukariotic proteasome (34, 35).
Fig. 4. Cα differences of each of the 14 different subunits of yCP. Cα dif-
ferences between average apo-structure and average complex structures
with (i) peptidic ligand bound to β5 (blue) or (ii) peptidic ligands also in
other active subunits (red). The associated error is computed from the SD of
the averaged coordinates (shaded regions). Dashed lines highlight residues
involved in the peptidic binding (black) and forming the H1 α-helix (red),
respectively.





























































































































The results from the HslV protease (33, 36, 37), thermoplasma
acidophilum 20S (30, 31), murine 20S (14), and the here re-
ported murine and yeast 20S analysis suggest that the displace-
ment of the α-helix H1 is a common allosteric trigger linking
the status of the active site with the entry gate into the proteasome
with diverse functional consequences (28, 29).
This question led us to analyze available structural data on the
yCP-open gate mutant where the N-terminal segment of the α3
subunit, which is central in the entangled structure of the entry
port, had been deleted (38). This mutation causes structural
disorder of the entry pore, which seals the particle lumen in the
WT species, thus opening an axial channel into the pro-
teolytically active inner chamber and displaying strongly en-
hanced peptidase activity. For that same reason, a comparison
with the proteasome component of the complexes with the 11S
activator and Blm10, respectively, which also display an open
entry port, was added (39, 40). Both molecular structures are
unliganded and lie in the apo-cluster region of the PCA, failing
to provide structural evidence for a reciprocal signal from the
gate to the active site in the sense of the described structural
alterations in β5. Other signals that escaped our analysis may
exist, and we are aware that possible conformational shifts can be
suppressed by constraints of the crystal lattice.
The discovery of two clusters of CP conformers and their specific
structural differences related to peptidic ligand binding in the yeast
system cannot, to our knowledge, offer a functional correlation
in the sense of enhanced affinity or binding rates of nonpeptidic
ligands that do not induce/require structural changes in β5, be-
cause of the lack of strictly comparable pairs of ligands. However,
recent work (41) showed substantial discrimination between cCP
and iCP and specificity for cCP by a nonpeptidic inhibitor in ac-
cordance with the structural features described here, but the con-
tribution of different side chain interactions cannot be singled out.
The mammalian system, however, offers a conspicuous cor-
relation between structural and functional data. The binding of
a peptidic ligand causes domain closure and movements of about
1 Å in yβ5 and similarly in mβ5c (Fig. 2). In contrast, mβ5i is in
a preformed configuration optimal for peptidic ligand (and
presumably substrate) binding in the apo state. The domains are
closed and geared up for peptide binding without requiring do-
main motion. These observations suggest that the formation of
the antiparallel β-sheet when the ligand peptide aligns with
protein segments containing residues T21, G47, and A49 is the
principal driving force for the overall change of the β5 backbone,
which is not restricted to neighboring protein segments, but
affects the entire subunit in various ways. The energies associ-
ated with these structural transitions of β5 and their propagation
to the adjacent subunits β4 and β6 are difficult to evaluate. It is
obvious, however, that they can contribute to the activation en-
ergy of ligand binding and may be major factors for the observed
enhanced activity of the immune proteasome mentioned earlier.
The presented study is relevant for pharmacology and specif-
ically for advanced design of ligands that discriminate between
cCP and iCP. There is experimental evidence for reduced toxicity
of specific immune proteasome ligands and added benefits in the
therapy of autoimmune disorders. We suggest that inhibitors
displaying the characteristic main chain bonding scheme of
peptidic ligands have a genuine preference for the iCP. Cer-
tainly, side chain and subsite interactions also have a major im-
pact in binding affinity and selectivity. Moreover, our findings
suggest that assisting or impeding the backbone shift of the distal
segments may have significant effects on affinity and kinetics of
peptidic inhibitors. The design of external binding inhibitors
distant from the active site therefore might emerge as an option.
In either case, molecular dynamics simulations, as shown here,
can be used to guide design and experiments.
Methods
Structural Classification of Reported PDB Structures. Currently the RCSB pro-
tein databank (42) lists 46 X-ray crystal structures of yCP together with four
Fig. 5. Intersubunit propagation of ligand-induced β5 structural changes. (A) Cα difference of β5 between the apo structure (1RYP) and the average non-
peptidic complexes (black); average peptidic complexes with β5 specific ligands (blue), and average peptidic complexes with ligands also in other active subunits
(red). Dashed lines and shaded regions presented as in Fig. 4. The colored bars on top highlight contact regions with neighboring subunits. The bold numbers
indicate five segments, distal from Thr1, where high variations are observed. (B) Subunits surrounding β5 (black structure) with H1 α-helix highlighted (red
dashed ellipsoid). (C) PCAmaps considering the contribution of the main chain atoms of the indicated residues. The five distal segments consist of residues 5–14,
30–41, 101–111, 138–154, and 179–186, respectively. In each map, numbers on the right upper and lower corners indicate the number of atoms involved in the
analysis and the distance in the PC1 axis between the closest elements of each cluster, respectively. Colored coding is according to Fig. 1. (D) The backbone
displacement of segment 4 is shown for yβ5, mβ5c, and mβ5i. The structures are colored as in Fig. 2. The arrows highlight the displacement occurring in yβ5 and
mβ5c on peptide binding. The dashed circle highlights the backbone of residues S141, R142, and S142 of yβ5, mβ5c, and mβ5i, respectively.













































































































































murine and one bovine CPs. This ensemble, including the here reported
structure in complex with the Boc-(Ala)3-al inhibitor, constitutes the cur-
rently available high-resolution structural information (Table S1). The
structures belong to two disjoint classes: structures with the active site oc-
cupied by peptidic inhibitors and structures in the apo-state or in complex
with nonpeptidic inhibitors. We define a CP ligand as peptidic if it aligns
antiparallel in between protein segments and establishes the corresponding
hydrogen bonds with Thr21N, Thr21O, Gly47O, and Ala49N (Fig. 2A), re-
gardless of a covalent bond with –Thr1.
PCA. PCA is a statistical tool that has been successfully applied to identify
protein domain motion (17–19). Given an ensemble of structures, the al-
gorithm consists of generating an average structure and using it as a com-









The matrix elements cij contain averaged information on the correlated
deviations of the atomic coordinates, xi and xj, from the corresponding en-
semble average, <xi> and <xj>. Diagonalization of C provides a space
transformation to represent these correlations in a set of orthogonal vec-
tors, thereby dissecting the global displacements into independent compo-
nents, and is performed by solving the eigenvalue problem
AtCA= λ: [2]
The matrix A represents the eigenvectors and λ represents the associated
eigenvalues. The magnitude of the eigenvalues reflects the magnitude of
the displacements described by its associated eigenvectors. We performed
a PCA analysis on the ensemble of β5 yeast crystal structures (Table S1 and SI
Methods) using the GROMACS (43) subroutines g_covar and g_anaeig.
MD Simulations. The MD simulations were performed using the GROMACS
(43) (v. 4.6.2) molecular simulation package (SI Methods).
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SI Methods
Principal Component Analysis. In the yeast system, we computed
the ensemble average of the main chain atoms of β5 after po-
sitional and orientational superimposition of all used crystal
structures, which are mostly derived from isomorphous crystal
forms (Table S2).
The principal component analysis (PCA) covariance was
computed considering the main chain coordinates (Cα, C, N)
from the 46 yeast proteasome core particle (yCP) structures
available in the Protein Data Bank (PDB) database (Table S1).
As the last 10 residues in mammalian β5/β5i differ considerably
from yeast, the covariance matrix was calculated considering
residues 1–106 and 108–192. Residue Arg107 is an insertion in
yeast and was also omitted. The PCA analysis was computed
using the GROMACS (1) subroutines g_covar and g_anaeig.
Molecular Dynamics Simulations. The starting coordinates of the
modeled systems, mcCP and miCP in their apo and complexed
forms, were taken from the respective refined crystallographic
structures (Table S1). The model consisted of two parts: (i) the
active part, which comprises the complete β5 and β6 subunits;
and (ii) the segments surrounding the active part (Table S3),
held in place by positional restraints applied to their Cα atoms.
All segments, with the exception of β7-T1, β3-S1, and β3-M204,
were capped with acetyl and methylamine groups at the N ter-
minus and C terminus, respectively. This truncated model of the
CP allows a reduction of the computational time while main-
taining the molecular surrounding of each active site as defined
by the crystal structures. The peptidic ligand used in the simu-
lations was a noncovalent Ala-Ala-Ala-NCH3 moiety. Its starting
backbone coordinates were taken from the backbone of the
crystallographic PR-957 complex, thus maintaining the hydrogen
bonds. During the simulations, positional restraints were applied
to the Ala Cαs and to the methyl carbon of the capping group.
The same setup and equilibration protocol were applied to all of
the modeled systems. Production runs consisted of 20 ns per-
formed in the NTP ensembleQ:1 and were carried out twice (Fig. 3
and Fig. S1).
All systems were simulated using the AMBER99SB all-atom
force field (2), an explicit water solvent scheme; and the TIP3
waterQ:2 molecule model (3), with 0.15 NaCl concentration and
a small surplus of ions for electric charge neutralization and
periodic boundary conditions. The long-range electrostatic in-
teractions were computed using fast particle-mesh ewald (PME)
(4), using a grid spacing of 1.2 Å. The van der Waals and short-
range electrostatic interactions were computed using cutoffs of
14 and 11 Å, respectively. The neighbor list was updated every
five steps. All bonds were constrained using LINCS (5), enabling
a simulation time step of 0.002 ps.
The following startup protocol was applied to all modeled
systems. First, two consecutive minimization processes with (i)
1,000 steps under the steepest descendant algorithm and (ii) 200
steps using conjugate gradient algorithm. Subsequently, to equili-
brate the system at 300 K, we performed 100 ps in the NVT en-
semble Q:3at 300 K using a V-rescale thermostat (τ = 0.1 ps) (6),
followed by 100 ps in the NTP ensemble using Parrinello-Rahman
(7) pressure coupling at 1 bar (τ = 0.1 ps). Finally, 20 ns of molecular
dynamics (MD) simulation was performed in the NTP ensemble,
maintaining the conditions from the last equilibration process.
Computation of Average Structures. For each CP subunit, the
coordinates were taken from the structures listed in Table S1 and
aligned with the yeast apo CP structure (1RYP) as reference.
From these aligned coordinates, the averages were computed for
apo- and pep-clusters of structures. To compare B-factors among
different structures, the B-factors of the main chain atoms for
each polypeptide chain were rescaled by Z-score (Eq. S1),
a statistical standardization method that allows a comparison
between B-factors from different structures (8, 9)
Z-scoreðresidue  of   residue  iÞ= ðB-factori − μÞ=σ; [S1]
where B-factor i is the B-factor of the ith residue. The average μ
and SD σ are computed from the B-factors of all N, Cα, and C
main chain atoms of the polypeptide chain.
Synthesis of Boc(Ala)3-CHO.
Boc-AAA-OMe. Boc-AA-OH (513 mg, 1.970 mmol), H-Ala-
OMe*HCl (250 mg, 1.791 mmol), and O-(7-azabenzotriazole-
1-yl)-N,N,N’N’-tetramethyluronium hexafluorophosphate (HATU)
(817 mg, 2.149 mmol) were dissolved in CH2Cl2 (20 mL) and
cooled to 0 °C before addition of N,N-diisopropylethylamine
(DIPEA) (1.251 mL, 7.16 mmol). The cooling bath was removed,
and the reaction was allowed to warm to room temperature for
2 h. The reaction mixture was washed with water (2 × 20 mL)
and brine (20 mL). The organic fractions were collected, dried
over MgSO4, filtered, and concentrated to give a colorless solid.
Flash column chromatography (100–0% petrol ether in ethyl
acetate) gave Boc-AAA-OMe (600 mg, 1.737 mmol, 97% yield)
as a colorless powder. 1H NMR (360 MHz, DMSO) δ =
4.36–4.17 (m, 2H), 3.14 (m, 1H), 2.69 (s, 3H), 1.37 (s, 9H),
1.30–1.23 (m, 9H). ESI-MS calculated Q:4for C15H28N3O6 [M+H],
346.20; observed, 345.75.
Boc-AAA-CHO. To a solution of Boc-AAA-OMe (100 mg, 0.290
mmol) in CH2Cl2 (dry) (3.5 mL) at −78 °C was added diisobu-
tylaluminium hydride (DIBAL-H, 1 M in hexane, 1.158 mL,
1.158 mmol). The reaction mixture was stirred at −78 °C for 90
min before it was quenched by addition of saturated NH4Cl (0.35
mL) and saturated potassium sodium tartrate (4 mL). The
mixture was stirred at room temperature for another 1 h and
extracted with CH2Cl2 (3 × 10 mL). The combined organic
phases were washed with H2O (15 mL) and brine (15 mL), dried
over Na2SO4, filtered, and concentrated in vacuo. The obtained
colorless powder of Boc-AAA-CHO was used without further
purification. ESI-MS calculated for C14H26N3O5 [M+H], 316.19;
observed, 315.83.





























































































































Crystallization and Structure Determination. Crystals of the 20S
proteasome from Saccharomyces cerevisiae were grown using
hanging drop method at 24 °C as previously described (10, 11).
Crystals were incubated for at least 72 h with Boc-Ala-Ala-Ala-al
(concentration: 50 mM in DMSO). The protein concentration
used for crystallization was 40 mg/mL in Tris·HCl (10 mM, pH
7.5) and EDTA (1 mM). The drops were composed of 3 μL of
protein and 2 μL of the reservoir solution, containing 30 mM of
magnesium acetate (MgAc2), 100 mM of morpholino-ethane-
sulphonic acid (Mes) (pH 6.8), and 10Q:5 % of 2-methyl-2,4-pen-
tandiol (MPD). Crystals were soaked in a cryoprotecting buffer
(30% MPD, 20 mM MgAc2, 100 mM Mes, pH 6.8) and flash-
cooled in a stream of liquid nitrogen gas at 100 K (Oxford Cryo
Systems) for data collection. The space group of the complex
belongs to P21 with cell dimensions of about a = 135 Å, b = 300
Å, c = 145 Å and β =113° (Table S4). Datasets were collected
using synchrotron radiation with λ = 1.0 Å at the X06SA-
beamline in SLS (Villingen, Switzerland). X-ray intensities and
data reduction were evaluated using the XDS program package
(12). Conventional crystallographic rigid body, positional, and
temperature factor refinements were carried out with REFMAC5
(13) using coordinates of the yeast 20S proteasome structure as
a starting model (PDB ID code: 1RYP) (14). For model building,
the programs SYBYL and MAIN (15) were used. The completed
complex structure yielded excellent R factors, as Q:6well as RMSD
bond and angle values. Coordinates were confirmed to fulfill the
Ramachandran plot (Table S1).
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Fig. S1. Molecular dynamics simulation. Second independent simulation ran under identical starting conditions as in Fig. 3, but with different initial velocities.





























































































































Fig. S2. B-factor differences all 14 subunits of yCP. B-factor differences between average apo-structure and average complex structures with a peptidic ligand
in β5 (blue) or with peptidic ligands also in other active subunits (red). The associated error is computed from the SD of the averaged Z-scores (shaded regions).
Dashed lines highlight residues involved in the peptidic binding (black) and forming the H1 α-helix (red), respectively.
Fig. S3. Superposition of ligands of the β5 subunit. Peptidic and nonpeptidic inhibitors are shown in red and black sticks, respectively.





























































































































Fig. S4. Cα difference against apo structures of the active subunits. Cα difference between the apo structure (1G0U) and the average nonpeptidic complexes
(black); average peptidic complexes with β5 specific ligands (blue), and average peptidic complexes with ligands in other active subunits (red). Dashed lines
highlight residues involved in the peptidic binding (black). On top of each plot, the secondary structure scheme is marked. The associated error is computed
from the SD of the averaged coordinates (shaded regions).





























































































































Table S1. Summary of used structures
PDB ID Molecule β5 β2 β1 Covalent PC1 PC2
Peptidic
1G65 (1) Epoxomicin + − − Yes −0.73 0.14
3MG4 (2) LXTa + − − No −0.14 0.18
3MG6 (2) LYTa + − − No −0.80 0.25
3MG7 (2) L2Ta + − − No −0.73 0.30
3MG8 (2) L3Ta + − − No −0.83 0.27
3NZJ (3) TMC-95A mimic 2a + − − No −0.23 −0.09
3NZW (3) TMC-95A mimic 2b + − − No −0.76 −0.02
3NZX (3) TMC-95A mimic 2c + − − No −0.56 −0.14
3OEU (4) PRD_000944 + − − No −0.77 0.24
3OEV (4) PRD_000959 + − − No −0.38 0.31
3OKJ (5) PRD_001051 + − − Yes −0.78 −0.03
3SDI (4) PRD_001071 + − − No −0.79 0.24
3SDK (4) PRD_001075 + − − No −0.81 0.22
4JSQ (6) TMC-95A mimic dimer 4e + − − No −0.34 −0.24
4JT0 (6) TMC-95A mimic dimer 4a + − − No −0.07 −0.15
4QBY (7) Boc-(Ala)3-al + − + Yes −0.03 −0.06
3BDM (8) Glidobactin A + + − Yes −0.09 −0.21
3GPJ (9) Syringolin B + + − Yes −0.23 −0.20
4INR (10) Vinyl Sulfone Lu102 + + − Yes −0.28 −0.19
4INT (10) Vinyl Sulfone LU122 + + − Yes −0.38 −0.20
4INU (10) Vinyl Sulfone LU112 + + − Yes −0.26 −0.25
4JSU (6) TMC-95A mimic dimer 3a + + − No −0.35 −0.24
1JD2 (11) TMC-95A + + + No 0.02 −0.12
2ZCY (8) Syringolin A + + + Yes −0.45 −0.04
2F16 (12) Bortezomib + + + Yes −0.29 −0.09
3D29 (13) Fellutamide B + + + Yes −0.82 −0.12
3MG0 (2) Bortezomib + + + Yes −0.28 −0.02
3UN4 (14) PR-957 Morpholine + + + Yes −0.33 −0.22
4GK7 (15) Syringolin-Glidobactin + + + Yes −0.10 −0.18
Apo/Nonpeptidic
2FAK (16) Salinosporamide A + + + Yes 0.65 0.03
3GPT (17) GPTa + + + Yes 0.65 0.05
GPW (17) Salinosporamide + + + Yes 0.61 0.04
4EU2 (18) k-7174 + + + No 0.94 0.18
1G0U (19) Open gate apo mutant − − − No 0.87 0.15
1RYP (20) Apo structrure − − − No 0.85 0.10
1VSY (21) Open gate Blm10 complex − − − No 0.95 0.19
1Z7Q (22) Open gate 11S complex − − − No 1.08 0.26
3L5Q (21) Open gate Blm10 complex − − − No 0.95 0.19
2GPL (23) BIQ* − + − No 0.71 0.03
3DY3 (24) Spirolactacystin D + − − Yes 0.75 −0.04
3DY4 (24) Spirolactacystin S + + − Yes 0.76 −0.05
3E47 (25) Homobelactosin C + − − Yes 0.84 0.12
3SHJ (26) Hydroxyurea (HU10) + − − No 0.70 −0.02
3TDD (27) Belactosin C + − − Yes 0.86 0.08
3UN8 (14) PR-957 Epoxy + − − Yes 0.58 −0.05
4LQI (28) Vibralactone + − + Yes 0.84 0.09
4J70 (29) Belactosin derivate 3e − + − Yes 0.90 0.14
Mammalian
1IRU (30) Apo Bovine − − − No 0.38 0.12
3UNB (14) PR-957 mouse + + + Yes −0.86 0.10
3UNE (14) Apo Mouse − − − No 0.39 0.11
3UNF (4) PR-957 mouse immuno + + + Yes −0.79 0.21
3UNH (14) Apo Mouse immuno − − − No −0.49 0.27
Column 1 corresponds to the classification of the 20S structures as peptidic, apo/nonpeptidic,
and mammalian. Columns 2 and 3 correspond to PDB ID of the 20S structure and ligand’s name,
respectively. Columns 4–6 indicate the presence (+) or absence (−) of the ligand at the active site
of subunits β5, β2, and β1, respectively. Column 7 indicate the whether the ligand binds co-
valently to the 20S. Columns 8 and 9 show the values plotted in Fig. 1, where PC1 and PC2
correspond to the projections of the each structure on the first two principal components of the
ensemble of yeast β5 structures, respectively.
*Small molecule ID in the PDB.
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Table S2. Unit cell parameters of the 20S structures shown in Table S1
Structure Space group Angle β (°) Length, α (Å) Length, β (Å) Length, γ (Å)
cCP bovine apo P 21 21 21 90.0 316.7 205.9 116.0
cCP mouse PR-957 P 1 21 1 106.6 171.7 198.6 226.8
cCP mouse apo P 1 21 1 108.07 171.0 201.3 226.0
iCP mouse PR-957 P 1 21 1 107.1 117.3 194.6 157.7
iCP mouse apo P 1 21 1 105.7 118.3 205.2 161.9
11S-yCP complex P 21 21 21 90.0 193.0 232.1 296.8
Blm10-yCP complex P 21 21 21 102.9 236.1 127.7 532.7
Yeast (average ± SD) P 1 21 1 112.9 ± 0.3 135.4 ± 1.0 300.7 ± 1.0 144.6 ± 1.0






β4 R19-F36, G48-Q61 and R95-V100
β7 1T-N3, H89-W107 and L122-V159
α4 S92-R108
α5 S54-I66, I80-V104 and D139-K141
α6 K58-I67, K79-D97
β2* D17-S30, S129-A133, T160-N172 and P190-T213
β3* S1-G7, K25- Q39, V131-W153, T165-V184 and T198-M204
β4* K126-T150 and K162-F171
*Subunits from the trans β ring.

































































































































Cell dimensions a = 135 Å, b = 300 Å, c = 145 Å, β = 113°
Molecules per AU* 1
Data collection
Beam line SLS, PX06SA
Wavelength (Å) 1.0
Resolution range (Å)† 20–3.0 (3.1–3.0)
No. observations‡ 586,676
No. unique reflections‡ 194,983
Completeness (%)† 92.4 (89.7)
Rmerge (%)
†,§ 8.6 (51.4)
I/σ (I)† 10.4 (2.3)
Refinement (CNS)
Resolution range (Å) 15–3.0
No. refl. working set 185,233
No. refl. test set 9,750
No. nonhydrogen 49,655




RMSD bond (Å/°)jj 0.005/1.10
Average B-factor (Å2) 68.7
Ramachandran plot (%)** 95.7/3.9/0.4
PDB accession code 4QBY
*Asymmetric unit.
†The values in parentheses of resolution range, completeness, Rmerge and I/σ (I) correspond to the
last resolution shell.
‡Friedel pairs were treated as identical reflections.
§Rmerge(I) = ΣhklΣj j[I(hkl)j − I(hkl)]j/Σhkl Ihkl, where I(hkl)j is the measurement of the intensity of
reflection hkl and <I(hkl)> is the average intensity.
{R = Σhkl j jFobsj − jFcalcj j/Σhkl jFobsj, where Rfree is calculated without a σ cutoff for a randomly
chosen 5% of reflections, which were not used for structure refinement, and Rwork is calculated
for the remaining reflections.
jjDeviations from ideal bond lengths/angles.
**Number of residues in favored region/allowed region/outlier region.
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ABSTRACT: In this study, we propose a novel approach to
evaluate virtual screening (VS) experiments based on the
analysis of docking output data. This approach, which we refer
to as docking data feature analysis (DDFA), consists of two
steps. First, a set of features derived from the docking output
data is computed and assigned to each molecule in the virtually
screened library. Second, an artificial neural network (ANN)
analyzes the molecule’s docking features and estimates its
activity. Given the simple architecture of the ANN, DDFA can be easily adapted to deal with information from several docking
programs simultaneously. We tested our approach on the Directory of Useful Decoys (DUD), a well-established and highly
accepted VS benchmark. Outstanding results were obtained by DDFA not only in comparison with the conventional rankings of
the docking programs used in this work but also with respect to other methods found in the literature. Our approach performs
with similar good results as the best available methods, which, however, also require substantially more computing time,
economic resources, and/or expert intervention. Taken together, DDFA represents an automatic and highly attractive
methodology for VS.
1. INTRODUCTION
In the early stages of the drug discovery process, large chemical
libraries are screened to identify lead molecules that allow the
development of new drugs. The large amount of experimental
resources that are required renders this search highly expensive
and time-consuming.1 In this context, in sillico virtual screening
(VS) has appeared as a fast and economic approach that
increases the efficiency of the lead discovery process.2−4
There are two main approaches to perform VS: ligand-based
and structure-based.5 In the former, previously known active
ligands are used to identify other molecules with similar
characteristics; in the latter, protein and ligand structural
models at atomic resolution are used to evaluate their binding
affinity. Structure-based methods perform generally better than
ligand-based methods in identifying new lead compounds.6 In
structured-based methods, the screening is performed by
docking each of the library’s molecules into the receptor’s
active site while optimizing the atomic interactions between the
binding partners.
Docking methods are foremost developed to identify the
ligand’s actual binding mode from the large set of sampled
conformations tested.7 In this regard, docking software like
Autodock, AutodockVina, and RosettaLigand have achieved
high performances.8−10 Compared to the discrimination of
correct and incorrect conformations of the same ligand, it is far
more challenging to discriminate active from inactive ligands, as
it is required for structured-based screening. This complication
arises from the difficulty to evaluate free energy terms of the
unbound ligand state, such as solvent and conformational
entropies. Whereas these terms cancel out when comparing
conformations of the same ligand, they do not cancel out when
treating different molecules. Nevertheless, due to the lack of
better ranking methods, it is common practice to rank ligands
based only on the docking score of their best docked
conformations.
Many attempts have been made to improve the ranking of
ligands beyond the accuracy obtained by using the plain
docking score.11−16 For instance, Garcıá-Sosa et al.14 reported
that a better correlation between docking scores and
experimental binding energies can be achieved by dividing
the docking score by the ligand’s size; resulting in a descriptor
often referred to as ligand efficiency (LE). Others have analyzed
several high ranking conformations per ligand, rather than
considering only the best scored conformations. For example,
Seok et al.15 augmented the binding energy evaluation by
adding an entropy term that was estimated from the
populations of clusters of high ranked binding modes. To
establish a new ranking, Wallach et al.16 compared scores of
query molecules with that of physically similar (molecular
weight, number of rotational bonds, number of hydrogen
acceptor/donor, etc.) but chemically dissimilar (different
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topology and functional groups) decoys. For each molecule in
the screening library, a set of decoys is generated. The approach
is based on the assumption that an active ligand should obtain a
significantly higher score than the decoys’ score distribution.
Although the method turned out as a success, its main
disadvantage is that the amount of molecules to be docked
increases by 2 orders of magnitude.
The common theme of the methods mentioned above is to
rank the screening library by a modified form of a single scoring
function. An alternative class of approaches attempts to
overcome the deficiencies of individual scoring functions by
employing two or more docking programs in a consensus
scheme.17 One of the most popular ways to combine multiple
ranked lists is the “rank-by-rank” approach.18 For each molecule
the average of its ranks is computed and used to establish the
final ranking list. A different method would be to average scores
from different scoring functions. It has been shown that both of
these methods rely crucially on the diversity and high quality of
the scoring functions.19 A more sophisticated analysis was
developed by Jacobsson et al.20 In their work, data mining
techniques were used to create “if−then” rules that yielded
upper and lower bounds to seven scoring functions.
Here we describe a novel framework to predict the ligand
activity based on a diverse set of docking features rather than
focusing on a single kind; such as the docking score. This
framework, which we named docking data feature analysis
(DDFA), converts this set of docking features into a feature
score. The signal conversion is performed by an artificial neural
network (ANN) that can be trained to work with data from
either single or several docking programs. In our particular case
we performed the analysis using three programs and five
docking features: (i) best docking score, (ii) ligand efficiency,
(iii) scores from similar molecules, (iv) the position of the
ligand’s poses within the general rank, and (v) structural
consistency of the ligand’s poses. These features were selected
to capture different aspects that are typically employed in a
human expert analysis to identify active binding molecules from
the VS ranking. Bearing this in mind, the docking score feature
represents the traditional approach, which assumes correlation
between score and activity. The ligand efficiency feature
contributes to a size independent comparison among ligands.
Monitoring the performance of chemically similar molecules is
inspired by the structural activity relationship (SAR) central
idea, which is that similar molecules have similar binding
energies. The feature that monitors the ranks of the ligand
poses assumes that poses from an active molecule are not
distributed randomly through the entire rank. The pose
variability feature exploits that active ligands often show better
converged poses. It is important to mention that the DDFA can
be easily extended and/or adapted to include other features.
To test the DDFA approach, we docked the broadly used
Directory of Useful Decoys21 (DUD) using three different
docking programsAutodock4,22 Autodockvina,9 and Roset-
taLigand23and predicted ligand activity. DUD is widely
accepted for benchmarking VS protocols. It consists of 40
receptors of pharmaceutical relevance and a screening library of
over 100 000 molecules. To predict the ligand activities for a
receptor of DUD benchmark, the DDFA ANN was trained
using 22 receptors from the remaining 39 data sets. The 22
receptors of the training set were randomly selected after
removing receptors with similar biological activity or with
reported positive cross-enrichment, with respect to the receptor
to be evaluated. We repeated this process with a different
receptor left out of the training set each time to obtain ligand
activity predictions for each receptor in DUD. As a control,
DDFA’s performance was compared to that of the individual
docking scores of the used programs and a consensus ranking;
with the latter generated by the ligand’s best rank in any
program. The performance evaluation was carried out using
well established and broadly accepted metrics, such as
enrichment factor (ef) and the area under the curve (auc)
from the receiver operator characteristic (ROC) curve.
2. METHODS
2.1. Docking Programs. In this study three docking
programs Autodock4.222 (AD4), Autodockvina1.29 (ADV),
and RosettaLigand3.423 (RL) were used. Although AD4 and
ADV were developed by the same lab, they differ in the
sampling methods and weights of individual score terms. RL is
part of the Rosetta’s software suite for modeling macro-
molecular structures. We used AD4 and ADV with a rigid
receptor model and RL with flexible side-chains for the
receptor.
2.1.1. Docking Using AD4 and ADV. The receptors and
ligands were prepared following the standard setup protocols
using Gasteiger partial charges.22 The grid sizes were set up to
27 Å × 27 Å × 27 Å in both programs, using as grid center the
center of mass of the ligand provided by the DUD to localize
the binding pocket. For AD4, the receptor grid was generated
using autogrid4 with 0.375 Å of grid spacing. The docking
parameter file was generated with the prepare_dpf42.py script
in AutoDockTools.22 The Lamarckian genetic algorithm with
default parameters was selected as pose search method.8 Ten
output poses were requested. For ADV, a maximum of ten
output poses was kept using a restriction of 3 kcal/mol in the
score difference between the best and worse poses. The global
search exhaustiveness parameter was set to 16 (default value 8).
2.1.2. Docking Using Rosetta Ligand. For Rosetta Ligand
(RL) the receptor side chain conformations were first
optimized with the f ixbb application of Rosetta.24 The ligands
were adapted to the RL format using scripts provided in the
Rosetta distribution (molfile_to_params.py).24 RL searches for
docking poses by cycling through a predetermined library of
intraligand conformations simultaneously to optimizing the
ligand’s rigid body degrees of freedom and receptor sidechain
dihedral angles. Usually the ligand conformational library is
generated with the external program OpenEye’s Omega.25
In the context of this work, ligand conformations were
already available through the AD4 and ADV docking output,
and thus, all output poses from AD4 and ADV were used for
the ligand conformation library of RL. For every run, the ligand
initial placement was provided by the center of mass of a
randomly selected member of the conformation library.
Docking was performed using the RossetaScripts26 application
with the parameters reported by Davis et al.27 The number of
runs per ligand was set to 50. The top ten structures in interface
score were selected for analysis and comparison with the other
docking software.
2.2. RAW Rankings. The screening library of each DUD
receptor was docked using the docking programs AD4, ADV,
and RL a ranking based exclusively on the docking score was
generated. A fourth ranking (ALL) was created by assigning to
each ligand the best achieved position within any of the
individual rankings. Tied cases were resolved by comparing the
ligand’s standardized docking scores of the individual programs.
Docking scores were standardized by subtracting the average
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and dividing by the standard deviation of the score-distribution.
This standardization procedure is commonly known as Z-Score.
We refer to this set of scores as RAW (RAW-AD4, RAW-ADV,
RAW-RL, and RAW-ALL) since they represent the most
straightforward approach to establish a ranking of a docked
library.
2.3. DDFA Rankings. In the DDFA approach, a feature
vector is assigned to each ligand and used as input layer of a
feed-forward ANN. The term “docking feature” refers to
characteristic information computed from the docking data of
the screened library. Details of the docking features used in this
work are given in section 2.4. The analysis was performed
considering docking data from either a single docking program
(DDFA-AD4, DDFA-ADV, and DDFA-RL) or from analyzing
all three sources simultaneously (DDFA-ALL). ANN’s
architecture and training procedure is described in section 2.5.
2.4. Docking Features. Docking data is analyzed to derive
features that help to discriminate between active and inactive
ligands. In this work five features are used in the analysis
(DockScore, DockLE, DockSimi, DockPoses, and DockRmsd)
and are described in the following sections.
2.4.1. DockScore. This feature is given by the best docking
score of the ligand poses. It represents the traditional approach,
in which the docking score helps to provide enough
information to discriminate an active molecule from an inactive
one. Prior to analysis the docking scores were standardized as
Z-scores.
2.4.2. DockLE. The ligand efficiency (LE) was computed as
the quotient between the best ligand’s score and the number of
heavy atoms of the ligand.
2.4.3. DockSimi. The DockSimi feature of a ligand is the
weighted average of the best docking scores of the five most
similar ligands in the docked library. The Tanimoto coefficients
(Tc) were used as both similarity measures and weighting
factors in the computation of the average. The FP2 molecular
fingerprints as implemented in OpenBabel28 version 2.3.1 were
used to compute the Tc. Only ligands with Tc > 0.70 were
considered as similar. Whenever no similar ligands existed in
the docked library, DockSimi was set to zero.
2.4.4. DockPoses. This feature is a five-dimensional vector
composed of the number of ligand poses that are within the top
5%, 10%, 15%, 20%, and 25%, respectively, of all pose-scores in
the docked library.
2.4.5. DockRmsd. This feature is a five-dimensional vector
given by the RMSD of the second−sixth ranked poses of a
ligand when superimposed to the first ranked pose.
2.5. Evaluation of Docking Features Using Artificial
Neural Networks. 2.5.1. Architecture of the ANN. Artificial
neural networks (ANNs) are known to perform well on pattern
recognition and classification problems.29 Here we train an
ANN to identify active molecules based on the information
provided by docking features.
Figure 1 shows a schematic representation of the ANN
topology. It consists of 13, 8, and 1 nodes for the input, hidden,
and output layers, respectively (Supporting Information Figure
S1). The network has full-connectivity among the layers, with
linear, sigmoidal, and softmax activation functions for the input,
hidden, and output layers, respectively. The ANN was
constructed using the PyBrain30 package. Given the ligand’s
docking features at the input layer, the returned value at the
ANN’s output node can be interpreted as a confidence
assessment on the ligand’s activity chances. Consequently the
ligands of the screened library are ranked based on the ANN’s
output. If DDFA is applied to a single docking program, the
docking features give rise to 13 input nodes as follows: one
node for features DockScore, DockLE, and DockSimi and five
nodes each for the features DockPose and DockRmsd. In the
DDFA-ALL, where DDFA is applied to three docking programs
simultaneously, the number of input nodes is tripled.
2.5.2. Training and Application of the ANN. In order to
apply the DDFA approach to any of the DUD receptor’s, the
docking data was divided into three nonoverlapping sets:
training, validating, and testing (Figure 2). The training set is
used during parameter estimation; the validation set is used to
control hyperparameters and to monitor training progress; the
test set is used to measure the performance of the methodology
as in the reported results. To test the method we use a leave-
one-out approach. Thus, one receptor and it’s DUD ligands are
used as the testing set and remaining receptors and associated
DUD ligands are used for training and validation. However,
because similarities between the receptor used for testing and
the receptors used for training or validation might cause
overestimation of the performance for truly new and unseen
cases, we further remove any receptors similar to the test
receptor from training and validation sets. As similar we
consider receptors in the same biological class (Table 1) and
also receptors for which positive cross-enrichment has been
reported21 (Table 1, column 2). Because this would cause
varying numbers of receptors in training and validation sets, we
further reduce their number to always get a total of 22
receptors, which reflects the smallest number of nonsimilar
receptors which would ever occur. This final selection is done
randomly. Thus, the analysis on the testing set represents a
realistic evaluation of the DDFA performance and similar
performance would be expected for unknown receptors and
screening ligands.
To generate balanced training and validation sets, all active
molecules are taken together with the same amount of
randomly selected decoys. From this pool with a balanced
active ligand to decoy ratio, 70% was used for training and 30%
for validation (Supporting Information Figure S2). The training
process was conducted under a back-propagation protocol with
a value of 0.001 for all three training parameters: weight decay,
learning rate, and momentum (Supporting Information Figure
S3). The testing set was used to monitor the ANN performance
over the training epochs. Training was terminated when a
plateau for the test-set performance had been reached. This
plateau occurred after 800 epochs for the AD4, ADV, and the
Figure 1. Schematic representation of the ANN used with single
docking program. The ANN has a feed-forward architecture consisting
of three layers with 13 and 8 nodes in the input and hidden layers,
respectively, and a single output node. There is full connectivity
among the layers using linear, sigmoid, and softmax as activation
functions for the input, hidden, and output nodes, respectively. A
detailed description of the input values taken by each of the input
nodes can be found in the Methods section. In the case where the
information from three docking program is used, the input layer nodes
are triplicated.
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ALL-scheme and after 1200 epochs for DDFA-RL (Supporting
Information Figure S4). After the training process, ligands from
the testing receptor were ranked based on the ANN’s output.
This ANN training procedure was repeated 40 times, each time
with a different set of the 40 receptors of DUD selected as the
testing receptor and thus excluded from the training and
validation sets.
2.6. VS Performance Evaluation. In order to evaluate the
performance of VS experiments, several metrics were computed
on the benchmark receptors based on the generated rankings.
These metrics are the area under the curve (auc) of the receiver
operator characteristic (ROC) curve for sensitivity versus
Figure 2. Flowchart depicting the cross-validation and application
procedures of the DDFA approach. VS data is separated into three
nonoverlapping sets: training, validation, and testing. The receptor to
be analyzed constitutes the testing set; any of its data is considered
during the training and validation processes (enclosed dashed region).
The training and validation sets are formed using 22 receptors. None
of these receptors can be similar to the receptor used for testing
(Table 1). Docking data belonging to all active molecules, together
with same amount of information from random selected decoys, is
partitioned into training and validation sets in a 70:30 ratio. The ANN
is trained under a back-propagation protocol using the training set,
whereas the validation set is used to monitor the ANN performance.
As final step, the trained ANN is applied to the test receptor.
Table 1. Similarity Relationships between Receptors as
Considered to Build Training and Validation Setsa
class: nuclear hormone receptors
receptor receptors with positive cross-enrichment

















TK ADA, COMT, ALR2, COX-1, GPB, PARP, PNP, SAHH
VEGFr2 none
class: serine proteases
receptor receptors with positive cross-enrichment
FXa DHFR, GART
thrombin DHFR, ERantagonist
trypsin PPARg, ADA, DHFR
class: metallo enzymes
receptor receptors with positive cross-enrichment
ACE ALR2
ADA none
COMT RXRa, ALR2, AmpC, PNP
PDE5 P38MAP
class: folate enzymes




receptor receptors with positive cross-enrichment
AChe FXa
ALR2 GART, ACE, RXRa, PPARg, AmpC, COX-1, COX-2
AmpC GART, ACE, RXRa, PPARg, ALR2, COX-1, COX-2
COX-1 ALR2, COX-2




HMGR RXRa, ACE, GART, ARL2,AmpC,COX-1
InhA none
NA PPARg, thrombin, trypsin, ADA
PARP COX-1, PNP
PNP TK, ADA, COMT, COX-1, GPB, PARP, SAHH
SAHH TK, ADA, COMT, COX-1, PARP, GPB, PNP
aThe 40 DUD receptors sorted in 6 biological classes. For a given
receptor used as test set, all receptors within the same classification
and in the list of reported cross-enrichment21 are excluded from
training and validation sets.
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specificity [eqs 1 and 2] and enrichment factor (ef) [eq 3].
These metrics were chosen due to their popularity and












To estimate the significance of the difference ΔX in a metric
X between a pair of methods, with X being either the auc or ef,
we compute the p-value on the average difference31


















Where erf is the error function, N is the number of receptors in
the DUD benchmark, and Var(ΔX) denotes the variance of
ΔX.
3. RESULTS AND DISCUSSION
We have developed a novel method for improving virtual
screening (VS) results called docking data feature analysis
(DDFA). In this approach, all ligands are docked several times
with different docking programs. Features derived from the full
library of docked poses and scores are assessed by an artificial
neural network (ANN) to identify potential active molecules.
To test our approach, we used the Directory of Useful
Decoys21 (DUD), which is an established VS benchmark
consisting of 40 receptors, each of them having its own
screening library with a 1:36 active to decoy ratio. The DUD is
a challenging test for receptor-based VS algorithms since the
decoys were selected specifically to be similar to the active
molecules of each receptor.21 Each of the 40 DUD libraries
were docked using three different programs: Autodock4.222
(AD4), Autodockvina9 (ADV), and RosettaLigand3.423 (RL).
Docking was conducted with a rigid receptor molecule in AD4
and ADV and with flexible receptor sidechains in RL. Two
rankings were generated from each of the three data sets: (i)
based on the docking score (RAW) and (ii) based on the novel
feature score (DDFA). Additionally, RAW and DDFA rankings
were generated by combining all three docking data sets
(denoted as RAW-ALL and DDFA-ALL). In the following we
compare the VS performance between the two ranking
approaches (RAW and DDFA) applied to the four docking
data sets (AD4, ADV, RL, ALL). To evaluate docking
performance, we computed the area under the curve (auc) of
the receiver operator characteristic (ROC) curve given by the
various rankings. An AUC of 0.5 reflects a random selection,
whereas a value of 1.0 reflects the perfect identification of active
compounds. As a second performance measure, we computed
the enrichment factor (ef), which compares the active-to-decoy
ratio computed at a given cutoff rank.
Compared to all three individual docking programs, DDFA-
ALL significantly improves the auc (Figure 3A, C, and E).
Notably, DDFA-ALL yields performances above the random
level (auc > 0.5) for all the receptors, with 30 of them
registering auc values above 0.7 (Table 2). In contrast, RAW-
AD4, RAW-ADV, and RAW-RL, yield good performance (auc
> 0.7) only in 11, 15, and 15 cases, respectively (Table 3). Even
more striking differences are observed in the number of
receptors performing poorly (auc < 0.5); with 13, 7, 7, and 0 for
RAW-AD4, RAW-ADV, RAW-RL, and DDFA-ALL, respec-
tively. In line with these results, DDFA-ALL obtains an average
auc of 0.77, which exceeds the corresponding values of RAW-
AD4, RAW-ADV, and RAW-RL by 28%, 20%, and 18%.
DDFA-ALL not only clearly outperformed the individual
scoring programs in the auc metric but also in the enrichment
factor (ef) (Figure 3B, D, and F). Within the first 20% of the
ranking, DDFA-ALL’s ef is around 50% larger than the efs of
the conventionally obtained rankings. Taken together, these
findings indicate that the DDFA-ALL is a robust method for
evaluating VS experiments, not only because it effectively yields
higher average performance in terms of auc and ef but also due
to its strong reduction of poor performing receptors.
Next we asked whether the remarkable gain in performance
of DDFA-ALL stems from the feature-based analysis of the
docking data or from the combination of complementary
docking programs. With this objective, we applied the DDFA
approach to the data from single docking programs.
Interestingly, these individual versions of DDFA still outper-
form the RAW approach (Figure 4) yielding 28, 27, and 28
receptors with auc > 0.7 for DDFA-AD4, DDFA-ADV, and
DDFA-RL, respectively, which has to be compared to the 11,
15, and 15 cases of good performance for RAW approaches
Figure 3. DDFA-ALL vs individual RAW rankings. DDFA-ALL is
compared against RAW-AD4 (A, B), RAW-ADV (C, D), and RAW-
RL (E, F). In plots comparing the auc (A, C, and E) the circles
represent each of the 40 DUD receptors. Plots comparing ef (B, D,
and F) show the DDFA-ALL to individual RAW average ratio. In all
the plots, the dashed line indicates the limit where both methods
perform equally.
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reported above. Also the number of receptors with auc < 0.5
remains low; the only two observed cases are angiotensin
converting enzyme (ACE) and heat shock protein 90 (HSP90),
for which auc of 0.40 and 0.47, respectively, are obtained with
DDFA-AD4 (Table 2). The average auc values, for DDFA-
AD4, ADDF-ADV, and ADDF-RL, are 0.74, 0.75, and 0.76,
respectively. These results still correspond to improvements of
23%, 17%, and 17% with respect to their RAW counterparts.
Also the ef improves with the DDFA individual versions
(Figure 4B, D, and F). For DDFA-AD4 and DDFA-RL, the ef
is around 50% larger than that of the corresponding RAW
version over the first 10% of the ranking, whereas for DDFA-
ADV this degree of improvement is just observed at the starting
point of the ranking. This analysis confirms the robustness of
the DDFA approach, since a significant enhancement in
performance is already obtained even when information from
a single docking program only is used.
The above-mentioned observation suggests that some part of
the performance gain in DDFA-ALL stems from the
combination of different docking programs. To assess this
influence, the RAW rankings of the docking programs were
combined in to a single list, RAW-ALL. Indeed, the RAW-ALL
ranking also outperforms individual RAW rankings (Figure 5A,
C, and E), although to a lesser extent than the DDFA-ALL
(Figure 5G). In the RAW-ALL approach, 21 proteins reported
auc values above 0.70; which exceeds the 11, 15, and 15 of
these cases for RAW-AD4, RAW-ADV, and RAW-RL,
respectively; but, it is still inferior to the 30 cases for DDFA-
Table 2. DDFA Rankings Metricsa
AD4 ADV RL ALL
efmax ef2% ef20% auc efmax ef2% ef20% auc efmax ef2% ef20% auc efmax ef2% ef20% auc
average 12.9 9.6 2.8 0.74 13.7 10.3 2.8 0.75 13.1 9.7 3.0 0.76 13.5 10.3 3.0 0.77
conf 95% 3.0 2.2 0.3 0.04 3.0 2.2 0.3 0.03 2.4 2.0 0.3 0.03 2.6 2.0 0.3 0.03
ACE 1.8 0.0 1.7 0.57 4.3 2.1 2.0 0.63 2.9 0.0 2.7 0.70 2.3 0.0 1.9 0.57
AChE 19.3 11.9 2.6 0.71 21.3 18.1 3.8 0.88 20.1 12.8 2.2 0.67 4.7 3.3 2.2 0.73
ADA 1.0 0.0 0.4 0.40 8.3 6.5 1.7 0.60 13.7 9.1 2.1 0.70 5.5 2.6 1.7 0.64
ALR2 20.4 16.3 3.4 0.81 31.4 27.5 4.0 0.87 23.5 17.7 3.3 0.74 19.6 15.7 3.9 0.85
AmpC 4.8 4.8 1.2 0.56 4.8 2.4 0.7 0.55 4.8 2.4 1.2 0.57 4.8 2.4 0.7 0.51
AR 7.3 5.8 2.7 0.78 23.3 17.5 4.0 0.88 5.1 3.2 1.4 0.54 9.7 9.7 3.9 0.82
CDK2 14.4 10.8 3.4 0.83 21.9 16.8 3.1 0.81 11.7 8.0 2.9 0.72 13.1 10.2 3.2 0.80
COMT 7.6 0.0 3.2 0.80 43.5 29.0 3.7 0.88 4.8 4.8 2.3 0.66 23.9 10.6 4.0 0.87
COX-1 8.7 8.7 2.9 0.75 29.1 16.6 3.8 0.83 12.5 10.4 3.2 0.71 24.9 14.5 3.6 0.82
COX-2 10.6 9.8 3.0 0.78 24.7 20.2 3.7 0.84 4.8 4.2 3.3 0.80 13.5 13.0 3.9 0.86
DHFR 17.2 12.8 4.0 0.89 12.1 9.4 3.0 0.79 19.5 18.6 4.6 0.95 19.5 15.9 4.2 0.91
EGFr 2.0 1.7 1.8 0.67 7.3 7.3 2.4 0.75 13.7 11.7 3.5 0.84 11.8 8.9 3.1 0.80
ERagonist 15.1 14.4 3.4 0.71 12.5 12.1 3.4 0.84 15.1 9.1 3.7 0.84 18.2 18.2 4.3 0.92
ERantagonist 27.2 21.0 3.3 0.84 6.9 6.6 3.2 0.77 19.1 15.8 3.2 0.84 8.2 6.6 3.3 0.79
FGFrl 7.5 7.5 2.0 0.62 5.9 5.0 2.5 0.73 2.1 1.3 1.6 0.61 4.2 2.9 1.6 0.57
FXa 9.2 5.6 1.6 0.58 5.6 4.5 1.9 0.62 11.2 6.9 2.3 0.65 7.1 5.0 1.6 0.61
GART 2.5 0.0 2.4 0.74 2.6 2.6 1.8 0.68 12.8 11.5 3.5 0.84 15.3 7.7 3.4 0.76
GPB 8.2 5.0 1.4 0.60 8.0 5.9 3.2 0.81 18.1 14.7 3.9 0.83 22.5 19.0 4.3 0.89
GR 14.2 11.6 2.8 0.76 10.5 7.2 1.3 0.65 2.6 1.3 1.2 0.55 4.5 3.9 1.5 0.61
HIVPR 20.3 14.0 2.6 0.72 18.6 14.9 2.9 0.74 16.9 13.2 3.4 0.80 15.5 10.9 2.6 0.76
HIVRT 8.4 8.4 2.1 0.57 16.9 10.5 2.1 0.66 12.1 5.9 1.8 0.61 9.7 9.4 2.3 0.66
HMGR 7.2 5.8 3.6 0.80 8.7 7.2 1.7 0.64 20.2 11.5 3.2 0.86 11.5 5.8 3.6 0.82
HSP90 1.1 0.0 0.8 0.47 3.3 1.4 2.7 0.68 5.5 2.7 1.8 0.67 1.4 0.0 1.4 0.62
InhA 25.1 18.2 3.6 0.80 34.6 21.2 3.5 0.81 29.5 17.3 3.2 0.76 23.4 17.5 3.8 0.84
MR 38.7 21.4 3.9 0.88 16.0 10.0 4.3 0.87 21.7 20.0 4.0 0.82 38.7 21.4 3.6 0.84
NA 8.0 8.0 2.4 0.71 8.3 7.2 2.6 0.68 5.2 5.2 3.7 0.80 16.0 11.5 2.5 0.74
P38MAP 2.8 2.8 1.7 0.62 8.0 7.2 3.1 0.77 3.1 2.4 2.0 0.67 4.5 3.7 2.5 0.71
PARP 40.7 28.7 4.7 0.95 9.4 7.5 4.4 0.89 33.5 26.4 4.9 0.96 31.3 25.7 4.6 0.95
PDE5 15.3 14.3 3.7 0.83 22.3 16.0 3.6 0.83 20.0 16.0 4.3 0.89 21.4 18.5 4.1 0.90
PDGFrb 11.9 9.8 3.4 0.81 5.3 4.2 1.6 0.66 12.5 9.5 3.3 0.80 5.4 5.1 2.4 0.68
PNP 8.8 7.2 3.2 0.75 13.0 9.3 3.4 0.75 10.9 9.3 2.8 0.81 10.9 9.3 3.1 0.77
PPARg 7.8 7.0 2.2 0.72 7.1 7.1 2.6 0.70 9.4 8.9 3.5 0.82 5.2 3.8 2.2 0.76
PR 13.3 6.3 4.6 0.90 2.6 1.9 2.0 0.67 11.3 11.3 3.0 0.77 19.0 19.0 4.0 0.85
RXRa 33.0 25.6 5.0 0.96 17.9 17.9 4.8 0.94 16.5 10.3 4.8 0.93 20.5 20.5 4.3 0.91
SAHH 2.0 0.0 1.5 0.53 3.8 1.6 2.3 0.72 25.7 24.7 4.3 0.90 16.1 15.5 3.8 0.80
SRC 20.4 18.0 4.0 0.87 12.1 11.1 3.4 0.82 7.0 5.1 2.9 0.77 9.6 8.8 3.0 0.83
thrombin 12.6 12.6 3.4 0.82 23.9 14.7 3.3 0.85 15.4 10.5 3.3 0.82 14.0 11.2 3.4 0.84
TK 2.9 0.0 2.5 0.66 1.8 0.0 0.7 0.62 3.0 0.0 1.6 0.54 4.6 2.3 2.3 0.61
trypsin 17.8 13.4 4.0 0.88 10.3 8.2 2.5 0.72 4.1 2.1 2.7 0.74 13.4 11.1 3.3 0.76
VEGFr2 19.2 13.6 2.9 0.77 22.5 14.0 2.9 0.76 21.4 14.0 3.2 0.79 16.8 11.8 2.9 0.77
aEnrichment factor (ef) at 2%, 20%, and maximal reached, in addition to the ROC auc. The bold values indicate the highest auc value achieved in the
given receptor.
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ALL. On the side of poor-performing receptors (auc < 0.5),
their number is reduced to four, which certainly improves with
respect to the individual RAW rankings, but not in comparison
with DDFA-ALL, with its zero cases with auc < 0.5. An
equivalent picture is observed with the ef metrics. RAW-ALL
outperforms the individual rankings (Figure 5B, D, and F), but
not DDAF-ALL where RAW-ALL is at least 20% smaller over
the initial 10% of the ranking (Figure 5H). These results
provide evidence on the beneficial effect that is obtained from
the combination of three docking data sources.
To evaluate the significance of the observed differences
between methods in the performance metrics auc and ef2%, we
computed their p-value31 (Methods). The comparison of the
four different versions of RAW and DDFA yields remarkably
low p-values (<1 × 10−3; Table4A). The further improvement
in auc achieved by DDFA-ALL with respect to DDFA-AD4,
DDFA-ADV, and DDFA-RL is confirmed by the low p-values,
0.02, 0.04, and 0.07, respectively (Table 4B). In contrast,
DDFA-ALL does not yield significantly better ef2% than the
individual versions of DDFA (Table 4B). Taken together,
DDFA is significantly better than RAW in both metrics,
whereas DDFA-ALL outperforms the individual versions of
DDFA only in the auc metric.
After confirming the significance of the results yielded by
DDFA, we wanted to assess their stability with respect to the
number of receptors used during the training and validation
process. The systematic reductions of receptors used for
training causes a gradual decay in performance for all four
Table 3. RAW rankings metricsa
AD4 ADV RL ALL
efmax ef2% ef20% auc efmax ef2% ef20% auc efmax ef2% ef20% auc efmax ef2% ef20% auc
average 7.8 5.6 2.0 0.60 9.7 7.1 2.1 0.64 7.7 6.2 2.1 0.65 9.3 7.4 2.6 0.70
conf 95% 2.2 1.9 0.4 0.06 2.7 2.3 0.3 0.05 1.7 1.6 0.3 0.04 2.1 2.0 0.4 0.05
ACE 2.1 0.0 1.0 0.38 1.3 0.0 0.8 0.36 1.0 0.0 0.5 0.33 1.2 0.0 1.2 0.35
AChE 1.9 1.9 1.3 0.52 5.4 4.8 2.8 0.68 1.0 0.0 0.7 0.45 2.9 2.4 2.3 0.61
ADA 1.0 0.0 0.0 0.36 1.2 0.0 0.9 0.50 2.3 0.0 1.3 0.67 1.5 0.0 0.6 0.57
ALR2 2.9 0.0 2.6 0.62 9.8 3.9 2.7 0.72 5.9 5.9 1.5 0.53 6.2 2.0 2.7 0.73
AmpC 1.1 0.0 0.2 0.39 1.0 0.0 0.2 0.25 1.0 0.0 0.5 0.43 1.0 0.0 0.2 0.30
AR 9.0 7.0 2.7 0.70 19.4 18.8 3.7 0.80 5.1 3.2 1.5 0.48 15.4 14.7 3.9 0.84
CDK2 8.6 4.3 2.1 0.56 13.1 10.9 2.1 0.62 4.4 2.9 1.6 0.60 8.6 6.5 2.5 0.63
COMT 1.4 0.0 1.4 0.48 32.6 14.5 1.4 0.49 4.8 4.8 0.9 0.58 10.9 9.7 1.8 0.55
COX-1 2.2 2.2 0.8 0.52 16.6 10.4 3.8 0.84 6.2 6.2 1.6 0.67 12.5 12.5 3.6 0.83
COX-2 7.8 7.3 2.8 0.75 25.6 23.0 4.0 0.87 4.0 3.3 2.6 0.74 18.8 17.3 4.3 0.90
DHFR 17.7 14.7 4.8 0.95 11.1 8.9 3.5 0.86 17.5 17.4 4.7 0.95 14.5 12.5 4.7 0.94
EGFr 1.7 1.5 1.2 0.55 2.5 1.1 1.7 0.61 7.0 6.0 2.6 0.74 4.9 3.6 2.2 0.72
ERagonist 21.2 18.2 3.1 0.79 18.2 18.2 3.3 0.80 16.7 12.1 3.6 0.82 18.2 15.9 4.6 0.93
ERantagonist 21.8 19.7 3.5 0.82 13.6 9.2 2.2 0.67 13.6 11.8 2.3 0.67 13.2 13.2 3.3 0.77
FGFrl 1.0 0.8 0.7 0.42 1.2 0.4 0.9 0.50 1.0 0.0 0.8 0.46 1.0 0.0 0.7 0.46
FXa 2.1 1.8 1.2 0.57 2.4 2.4 1.8 0.67 9.1 6.6 1.9 0.64 5.5 5.5 1.8 0.66
GART 4.4 1.3 4.0 0.88 2.9 0.0 2.6 0.77 5.6 5.1 3.5 0.82 3.9 1.3 3.9 0.85
GPB 1.0 0.0 0.1 0.19 2.9 2.9 1.2 0.51 10.4 9.8 3.5 0.78 6.3 2.9 3.2 0.82
GR 6.5 5.8 2.1 0.60 7.9 5.2 1.4 0.59 1.3 0.7 0.6 0.42 9.1 6.5 1.6 0.57
HIVPR 5.1 4.1 2.5 0.66 5.8 5.8 2.7 0.73 6.8 5.8 2.3 0.63 6.5 4.8 2.6 0.73
HIVRT 2.5 2.4 0.7 0.38 12.1 7.0 1.9 0.65 7.3 5.9 1.9 0.57 9.7 7.0 2.0 0.63
HMGR 3.9 2.9 1.7 0.63 1.2 0.0 0.7 0.45 2.9 1.4 0.9 0.72 1.9 1.4 1.4 0.62
HSP90 1.2 0.0 0.4 0.47 1.7 0.0 1.2 0.63 2.4 0.0 2.4 0.72 1.6 0.0 1.0 0.64
InhA 22.7 13.5 1.9 0.47 19.1 12.4 1.8 0.56 10.3 5.1 1.6 0.53 15.4 11.1 2.2 0.53
MR 15.5 10.7 4.6 0.88 23.3 23.3 4.0 0.84 16.7 16.7 3.3 0.81 21.7 16.7 4.0 0.84
NA 2.3 1.2 0.9 0.56 1.1 0.0 0.4 0.41 4.1 3.1 1.6 0.57 2.1 2.1 0.8 0.49
P38MAP 1.6 1.2 0.7 0.42 3.1 2.0 2.3 0.62 3.6 2.0 1.9 0.65 2.4 2.3 2.0 0.63
PARP 25.1 21.1 2.7 0.71 9.4 4.5 2.8 0.73 15.2 13.2 3.1 0.77 15.2 14.7 4.3 0.91
PDE5 11.7 6.9 2.3 0.63 11.7 8.0 2.0 0.64 10.6 9.2 2.6 0.76 15.3 9.7 2.9 0.75
PDGFrb 7.7 4.7 0.9 0.32 5.3 3.0 0.6 0.37 4.2 3.6 1.7 0.59 6.5 3.5 1.3 0.50
PNP 6.1 3.1 2.4 0.63 4.8 4.1 2.6 0.73 5.6 3.1 1.9 0.59 4.2 2.1 3.1 0.79
PPARg 1.2 0.0 1.1 0.48 4.7 3.5 1.8 0.66 7.1 5.9 2.7 0.75 3.5 1.8 1.9 0.63
PR 13.3 8.4 1.7 0.57 1.9 0.0 1.1 0.45 19.7 15.0 1.9 0.66 15.8 9.4 3.2 0.81
RXRa 16.5 15.4 5.0 0.97 33.0 28.2 4.3 0.93 17.9 17.9 4.0 0.85 28.2 28.2 5.0 0.98
SAHH 2.6 0.0 2.1 0.67 22.5 20.1 3.5 0.86 17.0 17.0 3.5 0.83 13.3 12.4 3.3 0.81
SRC 14.0 10.7 2.8 0.70 5.0 4.1 2.4 0.72 7.6 4.4 2.0 0.65 12.1 10.1 3.9 0.85
thrombin 8.4 7.0 2.8 0.74 11.2 8.4 3.0 0.71 7.0 7.0 2.4 0.65 11.2 9.1 3.1 0.79
TK 1.5 0.0 0.9 0.47 1.6 0.0 0.7 0.56 4.6 2.3 1.1 0.47 2.3 2.3 1.1 0.57
trypsin 17.8 14.5 3.7 0.85 8.2 4.1 2.5 0.67 3.1 3.1 1.7 0.56 8.2 6.2 3.5 0.83
VEGFr2 15.6 8.9 1.9 0.57 14.2 8.7 2.1 0.60 16.6 9.9 2.7 0.72 20.2 13.4 2.8 0.70
aEnrichment factor (ef) at 2%, 20%, and maximal reached, in addition to the ROC auc. The bold values indicate the highest auc value achieved in the
given receptor.
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DDFA cases (Figure 6), as expected when using less training
data. Nevertheless, DDFA performance is always at least as
good as the RAW performance (Figure 6; Table 3), such that
one can say with confidence that DDFA is robust in the sense,
that it never hurts average performance to use it. Moreover, we
should note that in this test we did not reoptimize the hyper-
parameters that control training for each number of receptors
such that one might be able to improve performance by hyper-
parameter tuning (Supporting Information Figure S5). The
result in Figure 6 also shows that the method has potential to
achieve an even better performance than demonstrated here, if
more receptors than 22 were available for training.
In addition to benchmarking the DDFA approach on DUD,
our study also provides valuable insight into the VS
performance of the individual docking programs (Table 3).
On average, RAW-ADV yielded better results than RAW-AD4
and RAW-RL. The superior performance of RAW-ADV over
RAW-AD4 in not surprising, since it matches with previously
reported observations.9,32,33 This is the first time, however, that
results for RL obtained on the DUD benchmark were
published. RL obtained averages values of 0.65 and 6.19 in
auc and ef2%, respectively, thereby yielding similar results to
ADV and better than AD4 (Table 3). This result is in line with
the outstanding performances that RAW-RL obtained in pose
recovery benchmarks.10,27,34 Table 3 shows that for three
receptors none of the docking programs reached auc values
above the random level: (i) angiotensin converting enzyme
(ACE), (ii) Amp-C beta lactamase (AmpC), and (iii) fibroblast
growth factor receptor 1 (FGFr1). These are the three
receptors for which DDFA-ALL yielded also the poorest
results with auc of 0.57, 0.51, and 0.57 for ACE, AmpC, and
FGFr1, respectively. This observation suggest that the
improvement produced by DDFA-ALL is somewhat limited
by the quality of the individual docking results. Another
interesting example is the platelet derived growth factor
receptor (PDGFrb), a receptor for which another seven
different scoring functions report auc values under 0.5.35 In
our hands, the aucs yielded by RAW-AD4 and RAW-ADV for
PDGFrb are also below 0.5, whereas RAW-RL obtains an auc of
0.59. In contrast, the performances of the individual version of
DDFA are undoubtedly better; 0.81, 0.66, and 0.80 for DFFA-
AD4, DDFA-ADV, and DDFA-RL, respectively.
As shown above DDFA represents a highly attractive
alternative to traditional ranking approaches for analyzing VS
experiments. This finding is also supported by comparing
DDFA performances with those found in the literature (Table
Figure 4. Individual DDFA vs individual RAW rankings. Individual
versions of both, DDFA and RAW, are compared for AD4 (A, B),
ADV (C, D), and RL (E, F). In plots comparing the auc (A, C, and E)
the circles represent each of the 40 DUD receptors. Plots comparing ef
(B, D, and F) show the individual DDFA to individual RAW average
ratio. In all the plots, the dashed line indicates the limit where both
methods perform equally.
Figure 5. RAW-ALL vs individual RAW and DDFA-ALL rankings.
RAW-ALL is compared against RAW-AD4 (A, B), RAW-ADV (C, D),
RAW-RL (E, F), and DDFA-ALL (G, H), respectively. In plots
comparing the auc (A, C, E, and G) the circles represent each of the
40 DUD receptors. Plots comparing ef show the RAW-ALL to
individual RAW average ratio (B, D, and F), and the RAW-ALL to
DDFA-ALL average ratio. In all the plots, the dashed line indicates the
limit where both methods perform equally.
Journal of Chemical Information and Modeling Article
dx.doi.org/10.1021/ci500028u | J. Chem. Inf. Model. 2014, 54, 1401−14111408
5). Considering structured-based methodologies tested on the
DUD benchmark, the different versions of the DDFA approach
(ALL, AD4, ADV, and RL) obtained performances that situate
them among the best methods available. Certainly, the
commercial docking software, ICM and Glide SP, achieve the
top performances in the auc and ef2% metrics, respectively.
Nonetheless, their corresponding performances fall within the
95% confidence limits of DDFA-ALL; auc 0.77 ± 0.03 and ef
10.3 ± 2.0 (Table 2). One of the best methods we also found is
the methodology developed by Durrant et al.37 in which
NNScore38 is used. This methodology resembles ours in the
sense that it combines academic docking software with an
artificial neutral network. However, while NNScore is trained
on the characteristic interactions of protein−ligand complexes,
thus proposing an interaction rescoring scheme, our DDFA is
trained on the characteristic features of the docking data
associated with active molecules, thereby representing a
reranking scheme. Additionally our DDFA approach also yields
high ef values at 2%, which, together with the averaged ef
curves presented previously (for example Figure 3), provide
confidence on the performance stability that our approach has
on this metric. These findings, together with the inherent
flexibility of DDFA (easily extended to combine several
docking programs and docking features), render our novel
approach as highly attractive for analyzing VS experiments.
3. CONCLUSION
The DDFA approach introduced in this work was able to
improve considerably the selection of active compounds from
the output of popular docking programs. This was achieved by
extending the analysis of the docking data beyond the
traditional docking score. Although the usefulness of rescoring,
consensus rankings, and machine learning methods has already
been noted,39−41 what distinguishes our study is that we could
convincingly show a possible way to combine all these elements
together synergistically. It must be emphasized, however, that
the success on combining several docking features and/or
scoring programs resides in their diversity.42,43 Each element
should account for different characteristics that contribute to
the active-decoy discrimination. Although establishing the
Table 4. p-Values of the Difference in Metrics (auc, ef2%) between Each Pair of Methods
a
(A) Significance of the Difference in Performance between RAW and DDFA
AD4 ADV RL ALL
RAW DDFA RAW DDFA RAW DDFA RAW DDFA
(0.60, 5.6) (0.74, 9.5) (0.64, 7.1) (0.75, 10.3) (0.65, 6.2) (0.76, 9.7) (0.70, 7.4) (0.77, 10.3)
p-value in auc <1 × 10−5 <1 × 10−5 <1 × 10−5 <1 × 10−5
p-value in ef2% <1 × 10
−5 3 × 10−4 <1 × 10−5 3 × 10−4
(B) Significance of the Difference in Performance between DDFA-ALL and the Individual Versions of DDFA
DDFA DDFA DDFA
AD4 ALL ADV ALL RL ALL
(0.74, 9.5) (0.77, 10.3) (0.75, 10.3) (0.77, 10.3) (0.76, 9.7) (0.77, 10.3)
p-value in auc 0.02 0.04 0.07
p-value in ef2% 0.27 0.59 0.42
aThe lower the p-value, the more significant the differences in performance.
Figure 6. Average auc on the DUD benchmark yielded by (A) DDFA-AD4, (B) DDFA-ADV, (C) DDFA-RL, and (D) DDFA-ALL, with a different
number of training receptors. The plotted values correspond to the average over five independent runs using a different subset of receptors. Error
bars correspond to the associated standard deviations.
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optimal docking feature selection for a given set of scoring
programs is a challenging task, it certainly opens a pathway to
possible further improvements.
In terms of the well-established virtual screening metrics, auc
and ef, DDFA performance is statistically similar to that
reported by commercial software under expert intervention35,36
or by methods that increase the computational cost by 2 orders
of magnitude.16 Additionally, DDFA shows an excellent
stability in its results and, in strong contrast to simple ranking
schemes, performs better than random selection for every
single receptor in the DUD benchmark. Overall, DDFA
represents a new, simple, and automatic reranking treatment
that not only is easy to implement and extend to other docking
software or docking data features but also provides high VS
performance with minimal extra computing time.
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Figure S1. Number of nodes in the hidden layer. 
Figure S2. Partition of the Train and Test Sets. 
Figure S3. Back propagation train parameters. 
Figure S4. Number training Epochs. 
 
Figure S1. Number of nodes in the hidden layer. The error on evaluating the Validation Set 
averaged over forty receptors for Autodock4 (A), AutodockVina (B), RosettaLigand (C), and 
ALL scheme (D). As the number of nodes increases, the standard deviation (shaded regions) 
is reduced and a faster convergence is obtained.  
 Figure S2. Partition of the Train and Validation Sets. The error on evaluating the Validation 
Set averaged over forty receptors for Autodock4 (A), AutodockVina (B), RosettaLigand (C), 
and ALL scheme (D).  
 
Figure S3. Back propagation train parameters. The error on evaluating the Validation Set 
averaged over forty receptors for Autodock4 (A), AutodockVina (B), RosettaLigand (C), and 
ALL scheme (D). The optimal performance curve (black) is obtained with by setting the 
parameters of back propagation trainer of pybrain to: momentum = 0.001, weight decay = 
0.001, and learning rate = 0.001. 
 Figure S4. Number training Epochs. The error on evaluating the Validation Set averaged over 
forty receptors for Autodock4 (A), AutodockVina (B), RosettaLigand (C), and ALL scheme 
(D). Training during 800 epochs appears to be sufficient for Autodock4, AutodockVina and 
the ALL scheme, whereas 1300 epochs are required for RosettaLigand.  
 
 
 Figure S5. Number training receptors. The error on evaluating the Validation Set averaged 
over forty receptors for Autodock4 (A), AutodockVina (B), RosettaLigand (C), and ALL 
scheme (D). The reduction of training information yields highly noisy data, although longer 
training may produce slightly better results.  
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